[{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","aka":[],"tldr":"The AACR Annual Meeting is where new modalities and targets debut, each April.","summary":"The AACR Annual Meeting, held each April by the American Association for Cancer Research, is where new modalities and targets debut. It holds basic, translational and early-clinical science, including first-in-human and platform data, and abstracts are free. The clinical trials plenaries and the emerging ADC and bispecific sessions are the ones to watch. On OnCo it is tagged source and congress, and the journal record Cancer Discovery links to it as the meeting behind much of what it publishes.","asOf":"2026-09-08","links":[{"label":"AACR Annual Meeting","url":"https://www.aacr.org/meeting/aacr-annual-meeting-2026/"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-discovery","cancer-research"],"dependsOn":[],"notes":[],"url":"https://www.aacr.org/meeting/aacr-annual-meeting-2026/","holds":"Basic, translational, and early-clinical science; first-in-human and platform data.","license":"Abstracts free","maintainer":"American Association for Cancer Research"},{"id":"genie","kind":"collection","name":"AACR Project GENIE","aka":[],"tldr":"AACR Project GENIE is real-world tumour sequencing data shared by leading cancer centres.","summary":"AACR Project GENIE holds clinico-genomic data on more than 200,000 sequenced tumours contributed by 19 institutions, making it a real-world tumour sequencing resource shared by leading cancer centres. The data are open through cBioPortal and Synapse, and the project is run by the American Association for Cancer Research (AACR). Its Biopharma Collaborative adds detailed outcomes for non-small cell lung, colorectal, breast, prostate, pancreatic and bladder cancers. On OnCo it is linked to the term Real-world evidence and cited by the bottlenecks Tumour heterogeneity and clonal evolution, Acquired resistance to every therapy, Data silos and Secrecy and intellectual property block collaboration, and by ideas such as Emulate the trial in real-world data first to decide which trials to run.","asOf":"2026-09-04","links":[{"label":"AACR Project GENIE","url":"https://www.aacr.org/professionals/research/aacr-project-genie/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.aacr.org/professionals/research/aacr-project-genie/","holds":"Clinico-genomic data on >200,000 sequenced tumours from 19 institutions.","license":"Open (via cBioPortal and Synapse)","maintainer":"AACR"},{"id":"acs-hope-lodge","kind":"collection","name":"ACS Hope Lodge","aka":[],"tldr":"Hope Lodge gives patients and a caregiver a free place to stay near the hospital when treatment is far from home.","summary":"Hope Lodge communities are run by the American Cancer Society in cities with major cancer centres. Patients in active outpatient treatment who live a set distance away can stay free with one caregiver, for as long as treatment lasts, with private rooms and shared kitchens and living areas. Referral comes through the treating hospital or the ACS helpline; demand is high and rooms are allocated by availability.","asOf":"2026-09-17","links":[{"label":"ACS Hope Lodge","url":"https://www.cancer.org/support-programs-and-services/patient-lodging/hope-lodge.html"}],"tags":["free","patient-programme"],"related":["american-cancer-society","acs-cancer-helpline","acs-road-to-recovery","corporate-angel-network","ronald-mcdonald-house-charities","nhs-healthcare-travel-costs-scheme","young-lives-vs-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.org/support-programs-and-services/patient-lodging/hope-lodge.html","holds":"Free lodging for cancer patients and one caregiver who must travel away from home for treatment, at Hope Lodge communities across the United States, with kitchens, laundry and shared spaces.","maintainer":"American Cancer Society"},{"id":"acs-road-to-recovery","kind":"collection","name":"ACS Road To Recovery","aka":[],"tldr":"Road To Recovery is the American Cancer Society's free volunteer driving service for getting to treatment appointments.","summary":"Many patients miss or delay treatment because they cannot get there. Road To Recovery matches patients who can walk unaided to volunteer drivers who take them to and from appointments at no cost. Rides are requested through the ACS helpline, ideally several days ahead, and coverage varies by area because it depends on local volunteers. Where no driver is available the helpline can suggest other transport help.","asOf":"2026-09-17","links":[{"label":"ACS Road To Recovery","url":"https://www.cancer.org/support-programs-and-services/road-to-recovery.html"}],"tags":["free","patient-programme"],"related":["american-cancer-society","acs-cancer-helpline","acs-hope-lodge","corporate-angel-network","ronald-mcdonald-house-charities","nhs-healthcare-travel-costs-scheme","young-lives-vs-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.org/support-programs-and-services/road-to-recovery.html","holds":"Free rides to and from cancer treatment in the United States, driven by trained volunteers, booked through the ACS helpline; availability depends on where volunteers are.","maintainer":"American Cancer Society"},{"id":"src-adc-review","kind":"collection","name":"ADC Review","aka":[],"tldr":"ADC Review covers everything ADC: deals, payload chemistry, and monthly pipeline summaries.","summary":"ADC Review covers everything about antibody-drug conjugates: news, deals, payload chemistry, conference coverage, a pipeline watch and the ADC database. It is published weekly by Sunvalley Communication and is free to read; the monthly 'Pipeline Watch' digest is the quickest ADC catch-up for anyone who has been away from the field. Its conference coverage and pipeline summaries are what make it useful alongside the structured databases. On OnCo it is tagged source and news, and the collection ADCdb / ADC Review links to it as its news-side counterpart.","asOf":"2026-09-08","links":[{"label":"ADC Review","url":"https://www.adcreview.com/"}],"tags":["source","news"],"related":["adcdb"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.adcreview.com/","holds":"Antibody-drug conjugate news, conference coverage, pipeline watch, and the ADC database.","license":"Free","maintainer":"Sunvalley Communication"},{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","aka":[],"tldr":"ADCdb and ADC Review are where to track the hundreds of ADCs in trials, with target, payload, and linker.","summary":"ADCdb and ADC Review together provide curated coverage and databases of antibody-drug conjugates in development, letting a reader track the hundreds of ADCs in trials by target, payload and linker. ADCdb is an academic database from Zhejiang University that structures more than 6,000 ADC records, while ADC Review, published by Sunvalley Communication, covers conference data from AACR, ASCO and ESMO. The licence is mixed across the two resources. On OnCo the collection is linked to the technology Antibody-drug conjugate (ADC) and to the separate ADC Review source record, and it is cited by the bottleneck Biomarkers are not validated or standardised.","asOf":"2026-09-04","links":[{"label":"ADCdb","url":"https://adcdb.idrblab.net"}],"tags":[],"related":["src-adc-review"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.adcreview.com","holds":"Curated coverage and databases of antibody-drug conjugates in development.","license":"Mixed","maintainer":"ADC Review (Sunvalley Communication); academic ADCdb (Zhejiang University)"},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","aka":[],"tldr":"A childhood-cancer charity started by a four-year-old patient's lemonade stand that now funds hundreds of grants and runs an open-science data lab for paediatric cancer genomics.","summary":"Founded 2005 after Alexandra Scott's fundraising (she died of neuroblastoma in 2004 at age 8). ALSF has awarded >$300 million in grants, runs the Childhood Cancer Data Lab (Philadelphia) whose refine.bio harmonises public transcriptomic data and whose OpenPBTA/OpenPedCan atlas underpins paediatric brain tumour research, funds the Crazy 8 initiative for the hardest paediatric cancers, and supports families' travel to treatment. Partner of the Children's Oncology Group and CHOP.","asOf":"2026-09-08","links":[{"label":"ALSF","url":"https://www.alexslemonade.org/"},{"label":"Childhood Cancer Data Lab","url":"https://www.ccdatalab.org/"}],"tags":["gap-fill","patient-org","paediatric"],"related":["neuroblastoma","medulloblastoma","osteosarcoma","ewing-sarcoma","wilms-tumor","retinoblastoma","rhabdomyosarcoma","hepatoblastoma","all-leukemia","alsf","paediatric-oncology-roadmap"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.alexslemonade.org/","holds":"Childhood cancer research grants, the Childhood Cancer Data Lab (open data tools including refine.bio and the Open Pediatric Cancer Atlas), Travel For Care assistance, and a paediatric trial finder.","license":"Data Lab tools open source","maintainer":"ALSF"},{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","aka":[],"tldr":"America's answer to UK Biobank, built for diversity.","summary":"The All of Us Research Program is America's answer to UK Biobank, built with diversity as its organising principle. It is a US cohort targeting one million participants with genomes, electronic health records and surveys, with an emphasis on groups under-represented in research. More than 250,000 whole genomes have been released, and linkage to health records enables models of cancer risk and outcome across ancestries. The programme is maintained by the NIH and is accessed through the registered tier of the Researcher Workbench. It is filed as a data collection alongside comparable population resources such as UK Biobank, and it matters to this corpus because ancestry-diverse cohorts are what allow risk and outcome models to be checked beyond European populations.","asOf":"2026-09-08","links":[{"label":"All of Us Research Program","url":"https://allofus.nih.gov"}],"tags":["data"],"related":["uk-biobank"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://allofus.nih.gov","holds":"US cohort targeting one million participants with genomes, EHR and surveys, emphasising under-represented groups.","license":"Registered tier via Researcher Workbench","maintainer":"NIH"},{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","aka":["ACS","cancer.org","Cancer.Net","src-cancer-org-asco"],"tldr":"The American Cancer Society is the largest US cancer charity. It publishes the annual US cancer statistics that most news reports quote, screening recommendations that differ from the US Preventive Services Task Force in places (colorectal screening from 45, for example), and plain-language patient guides for every cancer.","summary":"Founded 1913. Publishes Cancer Statistics annually in CA: A Cancer Journal for Clinicians (the most-cited oncology paper each year), Cancer Facts & Figures (including disparity-focused editions), and screening guidelines (e.g. colorectal screening from 45, 2018; lung, breast, cervical, prostate). Runs the Cancer Prevention Studies cohorts (CPS-II/3), the National Cancer Information Center (1-800-227-2345), Hope Lodge, Road To Recovery, and ACS CAN advocacy. Its patient content is a benchmark for readability.","asOf":"2026-09-08","links":[{"label":"Cancer Statistics 2026 (CA Cancer J Clin)","url":"https://acsjournals.onlinelibrary.wiley.com/journal/15424863"}],"tags":["gap-fill","patient-org","source","patient"],"related":["seer","globocan","cancer-gov-pdq","colorectal-screening","low-dose-ct-screening","mammography","acs-cancer-helpline","acs-road-to-recovery","acs-hope-lodge"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-health-disparities"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.org/","holds":"Cancer Facts & Figures annual statistics, screening guidelines, patient information in plain language for every cancer, the Cancer Survivors Network, lodging and transportation programmes, and a large extramural research grants portfolio. ASCO's former Cancer.Net patient content now lives on cancer.org.","license":"Copyright ACS; free public content","maintainer":"American Cancer Society"},{"id":"acs-cancer-helpline","kind":"collection","name":"American Cancer Society helpline","aka":[],"tldr":"The American Cancer Society answers 1-800-227-2345 every hour of every day, free, and can connect callers to its free rides and lodging programmes.","summary":"The ACS helpline is the largest cancer information service in the US. Specialists answer questions about cancer, treatment and side effects, point callers to local resources, and take requests for Road To Recovery rides and Hope Lodge stays. It is free and available in English and Spanish with interpreters for other languages.","asOf":"2026-09-17","links":[{"label":"American Cancer Society helpline","url":"https://www.cancer.org/support-programs-and-services.html"}],"tags":["free","helpline"],"related":["american-cancer-society","acs-road-to-recovery","acs-hope-lodge","nci-cancer-information-service","macmillan-support-line","cruk-nurse-helpline","cancercare","cancer-support-community","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.org/support-programs-and-services.html","holds":"The ACS National Cancer Information Center on 1-800-227-2345, open around the clock, with cancer information specialists, help finding lodging and rides, and a live chat; plus the Cancer Survivors Network online community.","maintainer":"American Cancer Society"},{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","aka":[],"tldr":"Arc's growing library of cell data, the fuel for virtual cell models.","summary":"The Arc Virtual Cell Atlas is the Arc Institute's growing library of cell data, the fuel for virtual cell models. It brings together curated and harmonised single-cell observational and perturbational datasets, amounting to hundreds of millions of cells, for model training, and it includes Tahoe-100M and scBaseCount. The atlas is paired with the Virtual Cell Challenge benchmark, so that models trained on its data can be compared on a common test. It is maintained by the Arc Institute and released openly. The collection is referenced by the virtual cell roadmap, the AI in oncology roadmap and the drug discovery roadmap, which traces the move from screening in mice to maps of dependency to designing in silico.","asOf":"2026-09-08","links":[{"label":"Arc Virtual Cell Atlas","url":"https://arcinstitute.org/tools/virtualcellatlas"}],"tags":["data","virtual-cell"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["arc-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://arcinstitute.org/tools/virtualcellatlas","holds":"Curated, harmonised single-cell observational and perturbational datasets (hundreds of millions of cells) for model training.","license":"Open","maintainer":"Arc Institute"},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","aka":[],"tldr":"ASCO guidelines are the American oncology society's guidelines, strongest on supportive care, survivorship, biomarker testing and resource-stratified recommendations for lower-income settings, complementing NCCN's algorithms.","summary":"ASCO guidelines (published in JCO, JCO Oncology Practice, JCO Global Oncology) follow GRADE-style methodology with systematic reviews and explicit evidence quality and strength ratings. Distinctive areas: antiemetics, growth factors, VTE, fertility preservation, palliative care integration, pain in survivors, geriatric assessment, financial toxicity, and resource-stratified guidelines (e.g. cervical, breast) developed with global partners; joint biomarker guidelines with CAP (HER2, ER, MMR/MSI); endorsements of other societies' guidelines. Also produces the ASCO Value Framework.","asOf":"2026-09-08","links":[{"label":"ASCO guidelines","url":"https://www.asco.org/practice-patients/guidelines"}],"tags":["gap-fill","guidelines"],"related":["nccn","esmo-guidelines","nice-guidance"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.asco.org/practice-patients/guidelines","holds":"Evidence-based US guidelines on treatment, supportive care, survivorship, biomarkers (joint with CAP) and resource-stratified guidelines for LMICs; rapid recommendation updates and provisional clinical opinions.","license":"Copyright ASCO; free access to guideline summaries","maintainer":"American Society of Clinical Oncology"},{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","aka":[],"tldr":"ASCO Daily News is the American Society of Clinical Oncology's free news service, published daily during meetings and weekly otherwise, covering sessions as they happen and guideline updates. It is most useful during the Annual Meeting, when it adds expert perspective to the abstracts.","summary":"ASCO Daily News is ASCO's own news service, holding meeting coverage, guideline updates and expert perspectives. It is published by the American Society of Clinical Oncology, daily during meetings and weekly otherwise, and it is free. It is at its best during the Annual Meeting, when it reports on the sessions as they happen and adds expert perspective to the abstracts. On OnCo it is listed as a source with the tags source and news, read alongside the ASCO Meeting Library for congress coverage and guideline updates.","asOf":"2026-09-08","links":[{"label":"ASCO Daily News","url":"https://dailynews.ascopubs.org/"}],"tags":["source","news"],"related":["src-asco-meeting-library"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://dailynews.ascopubs.org/","holds":"ASCO's news service: meeting coverage, guideline updates, and expert perspectives.","license":"Free","maintainer":"American Society of Clinical Oncology"},{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","aka":[],"tldr":"The primary record of what was presented at ASCO meetings each year.","summary":"The ASCO Meeting Library is the primary record of what was presented at ASCO meetings each year, holding abstracts, slides and posters from the Annual Meeting and the GI, GU, Breast and thematic meetings. The Annual Meeting is held each June in Chicago, with GI in January and GU in February, and the late-breaking abstracts are the market-moving ones. It is maintained by the American Society of Clinical Oncology; abstracts are free, slides are for members and registrants. On OnCo it is tagged source and congress, and the journal record Journal of Clinical Oncology links to it.","asOf":"2026-09-08","links":[{"label":"ASCO Meeting Library","url":"https://meetings.asco.org/meetings"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"url":"https://meetings.asco.org/meetings","holds":"Abstracts, slides, and posters from ASCO Annual Meeting, GI, GU, Breast, and thematic meetings.","license":"Abstracts free; slides for members/registrants","maintainer":"American Society of Clinical Oncology"},{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","aka":[],"tldr":"The ASH Annual Meeting is December's blood-cancer summit, bringing CAR-T, bispecifics, menin, BTK, and myeloma news.","summary":"The ASH Annual Meeting is December's blood-cancer summit, held by the American Society of Hematology and holding haematologic malignancy trials and science, with abstracts published in Blood. It brings the year's CAR-T, bispecific, menin, BTK and myeloma news in a single week. Abstracts are free, so the primary data can be read without attending. On OnCo it is tagged source and congress, and it is linked from the journal record Blood and the institution record American Society of Hematology.","asOf":"2026-09-08","links":[{"label":"ASH Annual Meeting","url":"https://www.hematology.org/meetings/annual-meeting"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ash"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"url":"https://www.hematology.org/meetings/annual-meeting","holds":"Haematologic malignancy trials and science; abstracts in Blood.","license":"Abstracts free","maintainer":"American Society of Hematology"},{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","aka":[],"tldr":"The ASTRO Annual Meeting is where hypofractionation, SBRT, protons, FLASH, and MR-guided radiotherapy results appear.","summary":"The ASTRO Annual Meeting, held each autumn by the American Society for Radiation Oncology, holds radiation oncology trials and technology. It is where hypofractionation, SBRT, proton, FLASH and MR-guided radiotherapy results appear. Abstracts are free. On OnCo it is tagged source and congress, and it is linked from the journal record International Journal of Radiation Oncology, Biology, Physics and the institution record American Society for Radiation Oncology.","asOf":"2026-09-08","links":[{"label":"ASTRO Annual Meeting","url":"https://www.astro.org/meetings-and-education/annual-meeting"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["astro"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["ijrobp"],"dependsOn":[],"notes":[],"url":"https://www.astro.org/meetings-and-education/annual-meeting","holds":"Radiation oncology trials and technology.","license":"Abstracts free","maintainer":"American Society for Radiation Oncology"},{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","aka":[],"tldr":"Australians are invited to free bowel, breast and cervical screening by age, and since 2025 to lung screening if they have a heavy smoking history.","summary":"Australia runs three long-standing population screening programs, each free to eligible residents and each with its own government page stating the age range: the National Bowel Cancer Screening Program posts a home test kit every two years, BreastScreen Australia offers mammography through state services, and the National Cervical Screening Program uses HPV testing every five years with the option to collect the sample yourself. A National Lung Cancer Screening Program using low-dose CT for people with a significant smoking history began in July 2025. Cancer Council Australia's 13 11 20 line answers questions about any of them.","asOf":"2026-09-17","links":[{"label":"Australia's national cancer screening programs","url":"https://www.health.gov.au/our-work/national-bowel-cancer-screening-program"},{"label":"BreastScreen Australia","url":"https://www.health.gov.au/our-work/breastscreen-australia-program"},{"label":"National Cervical Screening Program","url":"https://www.health.gov.au/our-work/national-cervical-screening-program"}],"tags":["free","public"],"related":["nhs-cancer-screening-programmes","ireland-national-screening-service","nz-time-to-screen","cdc-nbccedp"],"cancers":["colorectal","breast-cancer","cervical","nsclc"],"sections":[],"technologies":["colorectal-screening","mammography","low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.health.gov.au/our-work/national-bowel-cancer-screening-program","holds":"The National Bowel Cancer Screening Program (free home kit every two years), BreastScreen Australia (free mammograms) and the National Cervical Screening Program (HPV test every five years, with self-collection), plus a national lung cancer screening program that started in 2025.","maintainer":"Australian Government Department of Health"},{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","aka":[],"tldr":"A GitHub list of every cancer variant database, maintained by the community.","summary":"awesome-cancer-variant-resources is a community-maintained GitHub list of cancer variant knowledge bases and databases, curated by Sean Davis with contributions from the community and published under an open licence. It is a useful index of variant resources that reaches well beyond the databases catalogued individually on OnCo, and it is the kind of list OnCo points a reader to when they need a variant database not covered here. On OnCo it is cited by the idea An open knowledge graph linking trials, results, biomarkers, drugs and recommendations.","asOf":"2026-09-04","links":[{"label":"awesome-cancer-variant-resources","url":"https://github.com/seandavi/awesome-cancer-variant-resources"}],"tags":[],"related":["cosmic","civic","oncokb"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://github.com/seandavi/awesome-cancer-variant-resources","holds":"Community-maintained list of cancer variant knowledge bases and databases.","license":"Open","maintainer":"Sean Davis (community)"},{"id":"nihr-be-part-of-research","kind":"collection","name":"Be Part of Research (NIHR)","aka":[],"tldr":"Be Part of Research is the UK's free service for finding trials near you; taking part in NHS trials costs nothing and expenses are often paid.","summary":"Be Part of Research is run by the National Institute for Health and Care Research. Anyone can search studies by condition and postcode, or register to be contacted when a matching study opens. In the UK, taking part in an NHS-hosted trial is free, the study drug is supplied by the sponsor, and most trials reimburse reasonable travel costs, which the study team will state. It complements ClinicalTrials.gov, where every trial on OnCo is linked.","asOf":"2026-09-17","links":[{"label":"Be Part of Research (NIHR)","url":"https://bepartofresearch.nihr.ac.uk/"}],"tags":["free","public"],"related":["clinicaltrials-gov","lazarex-cancer-foundation"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://bepartofresearch.nihr.ac.uk/","holds":"The UK's public register of health studies looking for volunteers, including cancer trials, searchable by condition and location, with a sign-up service that contacts you when a suitable study opens.","maintainer":"National Institute for Health and Care Research"},{"id":"src-biocentury","kind":"collection","name":"BioCentury","aka":[],"tldr":"BioCentury writes analysis for people who make decisions about pipelines.","summary":"BioCentury writes strategic analysis of biopharma for people who make decisions about pipelines: regulatory trends, first-in-class approvals, China and deal terms. It publishes daily, and its monthly first-in-class approval tallies and its regulatory reform coverage are distinctive among the industry titles. Access is by subscription, so most of the analysis sits behind a paywall. On OnCo it is listed as a source with the tags source and news, read for the pipeline-level and regulatory view of oncology rather than for individual trial results.","asOf":"2026-09-08","links":[{"label":"BioCentury","url":"https://www.biocentury.com/"}],"tags":["source","news"],"related":["src-evaluate"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.biocentury.com/","holds":"Strategic analysis of biopharma: regulatory trends, first-in-class approvals, China, deal terms.","license":"Subscription","maintainer":"BioCentury Inc."},{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","aka":[],"tldr":"BioPharma Dive offers clean, free industry reporting and is good for deal and approval context.","summary":"BioPharma Dive offers clean, free industry reporting on approvals, trial results, mergers and acquisitions and policy, and is good for deal and approval context. It publishes daily and is run by Industry Dive, part of Informa. Access is free without a paywall, which sets it apart from the subscription industry titles. On OnCo it is listed as a source with the tags source and news, read for the industry side of oncology and for context on deals and approvals when a free explainer is needed.","asOf":"2026-09-08","links":[{"label":"BioPharma Dive","url":"https://www.biopharmadive.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.biopharmadive.com/","holds":"Industry news: approvals, trial results, M&A, policy.","license":"Free","maintainer":"Industry Dive (Informa)"},{"id":"breast-cancer-now-helpline","kind":"collection","name":"Breast Cancer Now helpline","aka":[],"tldr":"Breast Cancer Now's nurses answer 0808 800 6000 free, and the charity runs free courses and peer support for people finishing breast cancer treatment in the UK.","summary":"Breast Cancer Now is the UK's breast cancer research and support charity. Its helpline is answered by specialist nurses, its Someone Like Me service pairs callers with a trained volunteer who has had a similar diagnosis, and its Moving Forward courses help people adjust after treatment. Its information pages explain what the NHS provides free after surgery, including breast prostheses. All services for patients are free.","asOf":"2026-09-17","links":[{"label":"Breast Cancer Now helpline","url":"https://breastcancernow.org/"}],"tags":["free","helpline","patient-org"],"related":["nci-cancer-information-service","macmillan-support-line","cruk-nurse-helpline","acs-cancer-helpline","cancercare","cancer-support-community","krebsinformationsdienst"],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://breastcancernow.org/","holds":"Free UK helpline (0808 800 6000) staffed by breast care nurses, the Someone Like Me peer support service, Moving Forward courses after treatment, and information on free NHS breast prostheses and reconstruction.","maintainer":"Breast Cancer Now"},{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","aka":[],"tldr":"The Breast Cancer Research Foundation's weekly blog explains new breast cancer research findings and drug approvals in plain terms for a general audience, and reports on the research the foundation funds. It is free, and it bridges the research literature and patient-facing news.","summary":"The Breast Cancer Research Foundation publishes research-literate breast cancer news for a general audience: research news, approval explainers and updates on the research it funds. The blog is published weekly by the Breast Cancer Research Foundation and is free. It bridges the gap between the research literature and patient-facing news by explaining findings and approvals in plain terms. On OnCo it is tagged source and patient, and it is linked from the institution record Breast Cancer Research Foundation and the person record Evelyn Lauder.","asOf":"2026-09-08","links":[{"label":"Breast Cancer Research Foundation","url":"https://www.bcrf.org/blog/"}],"tags":["source","patient"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["bcrf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.bcrf.org/blog/","holds":"Research news, approval explainers, and funded-research updates.","license":"Free","maintainer":"Breast Cancer Research Foundation"},{"id":"bccss","kind":"collection","name":"British Childhood Cancer Survivor Study (BCCSS)","aka":["BCCSS"],"tldr":"Britain's own survivor cohort, built on national registration rather than on hospital volunteers, which is why it can follow people for half a century and count deaths that nobody reported. Its central finding is that what kills survivors changes with time: recurrence early, second cancers and heart disease late.","summary":"The BCCSS was established at the University of Birmingham by Mike Hawkins in 1998, funded by Cancer Research UK and the Kay Kendall Leukaemia Fund. Its original cohort was every person diagnosed with childhood cancer in Britain between 1940 and 1991 who survived at least five years: 17,981 people, assembled from national registration so that mortality and second cancers could be counted without anyone having to volunteer. A postal questionnaire sent through primary care physicians reached 14,836 eligible survivors and 10,483 returned it completed, 71 per cent of those eligible and 79 per cent of the 13,211 actually mailed by their doctor. The design paper describes it as \"the largest available population-based cohort of childhood cancer survivors to have included investigation of a wide spectrum of adverse outcomes\".\n\nThe 2010 mortality analysis followed those 17,981 survivors to the end of 2006. There were 3,049 deaths, 11 times the number expected, a standardised mortality ratio of 10.7 (95 per cent confidence interval 10.3 to 11.1). The ratio fell with time but was still threefold higher than expected 45 years from diagnosis (2.5 to 3.9). The important result is what changes underneath that. The absolute excess risk of death from recurrence fell from 97 extra deaths per 10,000 person-years (92 to 101) at 5 to 14 years from diagnosis to 8 (3 to 22) beyond 45 years. Over the same periods the excess from second primary cancers rose from 8 (7 to 10) to 58 (38 to 90) and from circulatory causes from 2 (2 to 3) to 29 (16 to 56). Beyond 45 years from diagnosis, recurrence accounted for 7 per cent of the excess deaths and second primary cancers and circulatory deaths together for 77 per cent.\n\nThe 2016 extension covered 34,489 five-year survivors diagnosed from 1940 to 2006 and followed to 28 February 2014. There were 4,475 deaths, 9.1 times expected (8.9 to 9.4), which is 64.2 excess deaths per 10,000 person-years (62.1 to 66.3). Survivors treated during 1990 to 2006 experienced 30 per cent of the excess number of deaths experienced by those treated before 1970, with the decline being 30 per cent for recurrence or progression and 60 per cent for non-neoplastic causes. Among survivors aged 50 to 59, subsequent primary neoplasms accounted for 41 per cent of excess deaths and circulatory conditions for 22 per cent; among those aged 60 or more the figures were 31 and 37 per cent. The authors state the practical consequence plainly: for survivors aged 60 or more, \"circulatory disease overtakes subsequent primary neoplasms as the leading cause of excess mortality\".\n\nThe limits are those of registration data. Non-fatal illness is captured only by questionnaire, so the chronic-condition prevalences that SJLIFE measures by examination are not available here; and a cohort beginning in 1940 carries treatments nobody uses now, which is exactly why the trend by era is the most useful thing in it.","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Cancer_survivor","links":[{"label":"The British Childhood Cancer Survivor Study: objectives, methods, population structure, response rates and initial descriptive information (Pediatr Blood Cancer 2008)","url":"https://doi.org/10.1002/pbc.21335"},{"label":"Long-term cause-specific mortality among survivors of childhood cancer (BCCSS) (JAMA 2010)","url":"https://doi.org/10.1001/jama.2010.923"},{"label":"Long term cause specific mortality among 34,489 five year survivors of childhood cancer in Great Britain (BCCSS) (BMJ 2016)","url":"https://doi.org/10.1136/bmj.i4351"},{"label":"Centre for Childhood Cancer Survivor Studies, University of Birmingham","url":"https://research.birmingham.ac.uk/en/organisations/centre-for-childhood-cancer-survivor-studies"}],"tags":["rejuvenation","survivorship","paediatric","late-effects","cohort","uk"],"related":["ccss","sjlife","pancaresurfup","rejuv-paed-late-mortality","rejuv-paed-uk-long-term-follow-up"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-real-world-evidence"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["A cohort that begins in 1940 describes treatments long abandoned. The figures by treatment era, not the overall ones, are what apply to a child treated today."],"url":"https://research.birmingham.ac.uk/en/organisations/centre-for-childhood-cancer-survivor-studies","holds":"Population-based cohort of five-year survivors of childhood cancer in Britain, linked to national death and cancer registration, with questionnaire data on health and social outcomes.","license":"Access by application to the Centre for Childhood Cancer Survivor Studies","maintainer":"Centre for Childhood Cancer Survivor Studies, University of Birmingham"},{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","aka":[],"tldr":"Find a mouse or dish model that matches a tumour type or mutation.","summary":"Cancer Models (the PDCM Finder) and the Human Cancer Models Initiative (HCMI) catalogue patient-derived cancer models, PDX, organoids and cell lines, with their molecular data, so a researcher can find a mouse or dish model matching a tumour type or mutation. PDCM Finder is run by EMBL-EBI and the Jackson Laboratory, HCMI by the NCI, and both are open; HCMI distributes next-generation models with clinical annotation. On OnCo the collection is tied to the technologies Patient-derived xenografts and Patient-derived organoids and to the Drug discovery roadmap. It is cited by the bottlenecks Lab models that fail to predict what happens in patients and Preclinical results do not reproduce, and by ideas such as Score every preclinical model by how often it predicted the clinical result.","asOf":"2026-09-04","links":[{"label":"Cancer Models (PDCM Finder) & HCMI","url":"https://www.cancermodels.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["pdx-models","organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancermodels.org","holds":"Patient-derived cancer models: PDX, organoids, cell lines, with molecular data.","license":"Open","maintainer":"EMBL-EBI / Jackson Laboratory; NCI HCMI"},{"id":"cruk-nurse-helpline","kind":"collection","name":"Cancer Research UK nurse helpline","aka":[],"tldr":"Cancer Research UK's nurses answer questions on 0808 800 4040, free, on weekdays; the About Cancer pages and Cancer Chat forum are there the rest of the time.","summary":"Cancer Research UK's information nurses take calls from patients, relatives and anyone worried about symptoms, explaining tests, treatments and trial results in plain terms. The same team maintains the About Cancer pages, which are among the clearest patient information in English and which OnCo cites, and moderates Cancer Chat, a free online forum. The line is free from UK phones.","asOf":"2026-09-17","links":[{"label":"Cancer Research UK nurse helpline","url":"https://www.cancerresearchuk.org/about-cancer"}],"tags":["free","helpline"],"related":["src-cruk-about-cancer","nci-cancer-information-service","macmillan-support-line","acs-cancer-helpline","cancercare","cancer-support-community","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancerresearchuk.org/about-cancer","holds":"Free confidential nurse helpline (0808 800 4040, Monday to Friday) alongside Cancer Research UK's About Cancer pages and the Cancer Chat online forum.","maintainer":"Cancer Research UK"},{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","aka":[],"tldr":"Cancer Research UK's About Cancer pages give clear UK patient information, including NHS treatment pathways.","summary":"Cancer Research UK's About Cancer pages hold patient information from symptoms to life after treatment in a UK context, including NHS treatment pathways. The pages are continuously updated, backed by a nurse helpline, and free to read; they are maintained by Cancer Research UK. They give clear UK patient information, including how treatment is organised in the NHS, where most patient sites are written for a US audience. On OnCo the source is listed with the tags source and patient, as the UK patient information counterpart to the US sites.","asOf":"2026-09-08","links":[{"label":"Cancer Research UK: About Cancer","url":"https://www.cancerresearchuk.org/about-cancer"}],"tags":["source","patient"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancerresearchuk.org/about-cancer","holds":"Patient information from symptoms to life after treatment, UK context.","license":"Free","maintainer":"Cancer Research UK"},{"id":"cancer-support-community","kind":"collection","name":"Cancer Support Community","aka":[],"tldr":"The Cancer Support Community runs a free helpline and dozens of local centres, including Gilda's Clubs, where anyone with cancer can join free groups and classes.","summary":"Formed by the merger of The Wellness Community and Gilda's Club, the Cancer Support Community is the largest professionally led network of free cancer support in the US. Its helpline is staffed by counsellors and navigators who can also help with finances and insurance questions, its centres run free support groups, exercise and nutrition classes, and its research institute studies the psychosocial needs of patients. Everything for patients and families is free.","asOf":"2026-09-17","links":[{"label":"Cancer Support Community","url":"https://www.cancersupportcommunity.org/"}],"tags":["free","helpline","patient-org"],"related":["nci-cancer-information-service","macmillan-support-line","cruk-nurse-helpline","acs-cancer-helpline","cancercare","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":["psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancersupportcommunity.org/","holds":"The Cancer Support Helpline (888-793-9355), free counselling and navigation, the MyLifeLine online community, and a network of local Cancer Support Community and Gilda's Club centres offering free programmes.","maintainer":"Cancer Support Community"},{"id":"cancercare","kind":"collection","name":"CancerCare","aka":[],"tldr":"CancerCare's oncology social workers give free counselling and support groups by phone and online to anyone in the US affected by cancer.","summary":"CancerCare has provided free professional support since 1944. Its staff are licensed oncology social workers who offer individual counselling, run support groups by phone and online, and help with practical problems such as transport and child care through small grants. Its Hopeline is free, and its publications and workshops are open to anyone. Financial assistance is limited to specific needs and is means-tested.","asOf":"2026-09-17","links":[{"label":"CancerCare","url":"https://www.cancercare.org/"}],"tags":["free","helpline","patient-org"],"related":["nci-cancer-information-service","macmillan-support-line","cruk-nurse-helpline","acs-cancer-helpline","cancer-support-community","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":["psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancercare.org/","holds":"Free counselling by oncology social workers, support groups, education workshops, publications and limited financial assistance for anyone affected by cancer in the United States, through the Hopeline 800-813-HOPE (4673).","maintainer":"CancerCare"},{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","aka":[],"tldr":"CancerNetwork publishes daily practice-oriented news across solid and haematologic cancers.","summary":"CancerNetwork, the online home of the journal ONCOLOGY, publishes daily practice-oriented news across solid and haematologic cancers. It holds news, reviews and the journal itself, and it is run by MJH Life Sciences, the publisher behind OncLive and Targeted Oncology. Access is free, without a paywall or registration wall. On OnCo it is listed as a source with the tags source and news, one of the daily clinician-facing feeds OnCo reads for practice-oriented coverage across both solid tumours and blood cancers.","asOf":"2026-09-08","links":[{"label":"CancerNetwork (ONCOLOGY)","url":"https://www.cancernetwork.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncology-williston-park"],"dependsOn":[],"notes":[],"url":"https://www.cancernetwork.com/","holds":"News, reviews, and the journal ONCOLOGY.","license":"Free","maintainer":"MJH Life Sciences"},{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","aka":[],"tldr":"cBioPortal lets you browse the mutations, copy number, and expression of tens of thousands of tumours without writing code.","summary":"cBioPortal for Cancer Genomics offers interactive exploration of more than 300 cancer genomics studies, including TCGA, MSK-IMPACT and AACR Project GENIE, so that a reader can browse mutations, copy number and expression across tens of thousands of tumours without writing code. Views include OncoPrints, survival plots, co-occurrence and pathway summaries, and an API supports programmatic access. The software is open source under the AGPL, with each study's data under its own terms, and it is maintained by MSK, Dana-Farber, Princess Margaret, Children's Hospital of Philadelphia and others. On OnCo it is linked to the technologies Comprehensive genomic profiling and Whole-exome and whole-genome sequencing, and cited by the bottlenecks Tumour heterogeneity and clonal evolution and Data silos.","asOf":"2026-09-04","links":[{"label":"cBioPortal for Cancer Genomics","url":"https://www.cbioportal.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cgp","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","dana-farber","princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cbioportal.org","holds":"Interactive exploration of >300 cancer genomics studies including TCGA, MSK-IMPACT, GENIE.","license":"Open source (AGPL); data per study","maintainer":"MSK, Dana-Farber, Princess Margaret, Children's Hospital of Philadelphia and others"},{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","aka":[],"tldr":"In the US, women with low income and no or little insurance can get free or low-cost breast and cervical screening through a CDC-funded programme in every state.","summary":"The National Breast and Cervical Cancer Early Detection Program has funded screening for uninsured and underinsured women since 1991. It works through grantees in every state, several tribes and territories, which arrange mammograms, Pap and HPV tests, diagnostic tests when screening is abnormal, and referral to treatment; in most states women diagnosed through the programme can get Medicaid coverage for treatment. Eligibility is by age, income and insurance status and the CDC page links to the local programme, which is where a woman applies.","asOf":"2026-09-17","links":[{"label":"CDC National Breast and Cervical Cancer Early Detection Program","url":"https://www.cdc.gov/breast-cervical-cancer-screening/"}],"tags":["free","public"],"related":["nhs-cancer-screening-programmes","australia-cancer-screening-programs","ireland-national-screening-service","nz-time-to-screen"],"cancers":["breast-cancer","cervical"],"sections":[],"technologies":["mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cdc.gov/breast-cervical-cancer-screening/","holds":"Free or low-cost mammograms, Pap and HPV tests and diagnostic follow-up for women in the United States with low income and little or no insurance, delivered through state, tribal and territorial programmes.","maintainer":"US Centers for Disease Control and Prevention"},{"id":"civic","kind":"collection","name":"CIViC","aka":[],"tldr":"CIViC is an open, Wikipedia-style database of what cancer mutations mean for treatment.","summary":"CIViC holds community-curated clinical interpretations of variants in cancer, in an open, Wikipedia-style model where each evidence item is linked to the publication it came from. It is run by Washington University in St Louis through the Siteman Cancer Center, released under CC0, and both the code and the data are open. CIViC was a founding member of the GA4GH VICC meta-knowledgebase. On OnCo it appears alongside Cancer variant knowledgebases and molecular tumour boards and Clinical NGS bioinformatics and variant interpretation, and it is cited by the bottleneck Knowledge reaches practice too slowly and by ideas including Every tumour genomic report machine-readable and deposited nationally and An open knowledge graph linking trials, results, biomarkers, drugs and recommendations.","asOf":"2026-09-04","links":[{"label":"CIViC","url":"https://civicdb.org"}],"tags":[],"related":["variant-knowledgebases"],"cancers":[],"sections":[],"technologies":[],"targets":["ctnnb1","ccnd1","tert","pole","apc","fgfr4","pold1","nrg1","tsc1","mycn","setd2","tsc2","calr","esr2","pml","smad2","jak3","yes1","tyk2","ephb2","syk","dpyd","tubb3","blk","prkcb","hdac9","psmd4","pdcd1lg2","rrm2","psmb8","ephb4","sstr5","scn8a","csf2rb","mgmt-protein","ugt1a1","csf1","mcl1","nudt15","vhl","pten","atm","cdkn2a","h3-3a","notch1","smad4","mlh1","dicer1","rb1","hras","smarcb1","smarca4","stk11","bap1","arid1a","ercc2","kmt2d","runx1","palb2","wt1","cebpa","fbxw7","msh2","chek2","msh6","cdh1","bcor","atrx","gnas","sf3b1","asxl1","etv6","cbl","pik3r1","kmt2c","kdm6a","pbrm1","pms2","crebbp","nfe2l2","ep300","cdk12","ccne1","bard1","brip1","rad51c","ddx41","lrp1b","rad51d","mapk1","flcn","nbn","srsf2","spop","u2af1","myc-gene","setbp1","gata2","map3k1","casp8","gnaq","sdha","fbxo11","cdkn1b","pik3cb","nf2","fat1","ppp2r1a","smad3","ccnd2","keap1","stag2","sh2b3","rad50","axin2","prkar1a","notch2","rad51b","rac1","gna11","foxa1","sos1","pot1","gata1","mitf","fancc","mecom","fanca","h3c2","plcg1","arhgap35","arid2","map2k4","stat3","lztr1","ercc4","ctcf","myod1","rhoa","arid1b","gata3","nt5c2","drosha","hgf","bcl11a","rasa1","hoxb13","fh","b2m","kdm5c","cic","mdm4","cdkn1a","mbd4","fhit","foxp1","rras2","araf","etv1","pax5","spen","ptprb","jun","ebf1","myb","pim1","ercc5","prex2","pdgfb","cdkn2b","mn1","ptprt","pik3r2","nr4a3","fubp1","foxo1","sdhb","il7r","erg","ercc3","fgf2","msh3","sufu","pax8","h3-3b","prdm1","ubr5","klf5","ddx3x","klf4","card11","tet1","cblb","ccnd3","fgf4","tbl1xr1","bcl10","rictor","abl2","mre11","fgf3","etv5","etv4","yap1","tfeb","prkn","crlf2","fcgr2b","fn1","cdx2","ereg","myd88","birc6","btg1","mycl","egf","nsd2","tcf3","ciita","birc3","bcl6","nfkbie","atg7","pou5f1","zrsr2","pcbp1","fas","tnfaip3","actb","rel","ercc6","tnfrsf14","p2ry8","rabl3","bach2","dcc","pou2af1","stat6","eif1ax","stat1","irs2","znf217","areg","rad54l","fancl","cul3","flt3lg","rfx7","klf2","hla-b","xrcc1","zfp36l1","mmp2","tgfa","socs1","prps1","cd44","rit1","ercc1","zeb1","abcb1","aurka","ptprd","fgf19","igf2","tbxt","sgk1","foxl2","map2k7","atp7b","atxn7","mir21","gna13","actl6a","aldh1a2","cdk9","ceacam1","fos","foxr2","hsph1","lgr5-gene","mir218-1","mthfr","mybl1","ncoa3","nqo1","nr4a2","plcg2","prkdc","slfn11","tnc","mef2b","bcl7a","kmt2b","sin3a","gnai2","hla-c","smarca2","ass1","atxn1l","birc5","birc7","ccne2","cdc50a","chek1","cip2a","crkl","ctag1b","cul7","eif4ebp1","emsy","errfi1","faap20","fcgr2a","fcgr3a","gas6","gstp1","hnrnph1","hoxc10","klln","mki67","notch3","pbk","ppp2r2a","ptprf","sirt1","slc12a2","slco1b1","timp1","tspyl1","setd1b","btg2","tmsb4x","id3","mga","nfkbia","pou2f2","ptpn6","tfap4","cd58","cysltr2","klhl6","usp7","dtx1","sp140","ube2a","abcc10","abcc3","abcg2","acta1","aebp1","agr2","aimp2","alcam","ascl1","asns","atg12","aurkb","b4galt1","bmp7","cblc","ccn2","cd83","cdk2","cdk5","cflar","chd8","ctag2","cx3cl1","cxcl10","cyp2d6","dazap1","ddx43","defa1","dkk1","drd5","dusp2","dusp6","ecscr","eif4a1","ets1","ets2","fbxw11","fgf13","fntb","fosb","foxc2","foxf1","foxp3","gadd45a","galnt14","grhpr","h1-2","h1-3","h1-5","h2ac17","h2ac6","h2bc12","h2bc5","h3c14","h3c4","hbb","hla-dra","hmox1","hnrnpu","hoxd8","hsp90b1","hspa5","hspb1","hvcn1","ifngr1","il33","il4r","irf8","itpkb","kdm5d","kif23","klhl14","krt18","lepr","ltb","mageh1","mef2c","mef2d","mertk","mmp1","mmp9","mpeg1","mus81","naprt","nedd9","nfkbiz","nol9","nptxr","nr2f2","orc1","osbpl10","ovol2","pappa2","pbld","pcna","pdcd4","pim2","plk1","pole4","ppp1r15a","prkaa2","prncr1","prom1","ptp4a3","ptpn12","pttg1","pxdnl","rad23b","rheb","robo4","rps6","rsf1","s100b","s1pr1","s1pr2","slc29a1","sncaip","sox10","sphk1","spry2","stag2-as1","stag3","stmn1","tbk1","tcf19","tf","tff3","tgfbr3","thbs2","tlk2","tox","tp53bp1","tpt1","ttf1","ubtf","ugt1a","vegfc","vps37a","wdr12","wnk1","wnt11","wnt6","xrcc3","zhx2","znf292","znf703"],"drugs":[],"companies":[],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://civicdb.org","holds":"Community-curated clinical interpretations of variants in cancer.","license":"CC0","maintainer":"Washington University in St. Louis"},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","aka":[],"tldr":"ClinicalTrials.gov is the master list of clinical trials. Every trial on this site links to its record.","summary":"ClinicalTrials.gov is the registry and results database of more than 500,000 clinical studies worldwide, run by the NIH National Library of Medicine and released as public domain US Government work. Registration is mandatory for US trials, and API v2 gives structured access to eligibility criteria, arms, outcome measures and posted results, which makes it the backbone of any trial-matching tool. Every trial on OnCo links to its ClinicalTrials.gov record, and the collection is tied to the technology AI trial matching and clinical decision support. It is also cited by bottleneck records including Trials enrol too few, too slowly, Failures are hidden, Data silos and Weak real-world evidence and registries, and by ideas such as One standing umbrella trial for all rare cancers in a country.","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov","url":"https://clinicaltrials.gov"}],"tags":[],"related":["trial-modernisation-roadmap"],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://clinicaltrials.gov","holds":"Registry and results database of >500,000 clinical studies worldwide.","license":"Public domain (US Government)","maintainer":"NIH / NLM"},{"id":"clinvar","kind":"collection","name":"ClinVar","aka":[],"tldr":"Whether a genetic variant is thought to cause disease, according to the labs that have seen it.","summary":"ClinVar is the public archive of variant interpretations submitted by clinical laboratories, recording whether each variant is thought to be pathogenic, benign or of uncertain significance according to the labs that have seen it. It is maintained by NCBI and released as public domain data. Because submitters can disagree, ClinGen expert panels resolve conflicting interpretations, and the archive is essential for interpreting germline BRCA and Lynch syndrome variants. On OnCo it is linked to the technology Germline (hereditary) testing and the terms Variant of uncertain significance (VUS) and Germline vs somatic mutations, and it is cited by the bottleneck Inherited risk is mostly unidentified and the idea Test every possible mutation in every cancer gene so no result is 'uncertain'.","asOf":"2026-09-04","links":[{"label":"ClinVar","url":"https://www.ncbi.nlm.nih.gov/clinvar/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vus","germline-vs-somatic"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.ncbi.nlm.nih.gov/clinvar/","holds":"Public archive of variant interpretations (pathogenic, benign, VUS) from clinical labs.","license":"Public domain","maintainer":"NCBI"},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","aka":[],"tldr":"The Colorectal Cancer Alliance is the largest US colorectal cancer patient organisation, focused on screening uptake from age 45, young-onset disease and connecting patients with biomarker-matched trials.","summary":"Founded 1999. Runs the toll-free helpline and certified navigators, the 'Lead From Behind' and 'Never Too Young' campaigns on early-onset colorectal cancer (now ~12% of cases and rising), Project Cure CRC ($100 million research commitment), BlueHQ patient platform and the annual AllyCon. Partners with Fight CRC and the Colon Cancer Coalition; advocates for screening coverage without cost-sharing.","asOf":"2026-09-08","links":[{"label":"Colorectal Cancer Alliance","url":"https://colorectalcancer.org/"},{"label":"Fight Colorectal Cancer","url":"https://fightcolorectalcancer.org/"}],"tags":["gap-fill","patient-org"],"related":["colorectal","colorectal-screening","msi","kras","sidedness"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://colorectalcancer.org/","holds":"Patient navigation helpline, BlueHQ community and resources, screening awareness campaigns (45+), the Project Cure CRC research fund, and biomarker education (MSI, KRAS, BRAF, HER2).","license":"Copyright CCA","maintainer":"Colorectal Cancer Alliance"},{"id":"corporate-angel-network","kind":"collection","name":"Corporate Angel Network","aka":[],"tldr":"Corporate Angel Network flies cancer patients to distant treatment for free, in empty seats on company jets.","summary":"Since 1981 Corporate Angel Network has arranged free flights for patients who need to reach a treatment centre far from home, using seats that would otherwise be empty on corporate flights. There is no financial eligibility test; patients must be medically stable and able to board unaided, and flights depend on where corporate aircraft are going. It is particularly useful for people travelling to trials at a distant centre.","asOf":"2026-09-17","links":[{"label":"Corporate Angel Network","url":"https://www.corpangelnetwork.org/"}],"tags":["free","patient-programme"],"related":["acs-road-to-recovery","acs-hope-lodge","ronald-mcdonald-house-charities","nhs-healthcare-travel-costs-scheme","young-lives-vs-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.corpangelnetwork.org/","holds":"Free flights for cancer patients, bone marrow donors and recipients travelling to treatment or trials in the United States, using empty seats on corporate aircraft; patients must be able to travel without medical support.","maintainer":"Corporate Angel Network"},{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","aka":[],"tldr":"COSMIC, the Catalogue of Somatic Mutations in Cancer, is the largest curated catalogue of mutations found in tumours, run by the Wellcome Sanger Institute. It also holds the Cancer Gene Census of around 750 genes, the reference mutational signatures and a cell line project; academic use is free, industry needs a licence.","summary":"COSMIC, the Catalogue of Somatic Mutations in Cancer, is the largest curated catalogue of somatic mutations and is often described as the encyclopaedia of cancer mutations. Alongside individual mutations it carries the Cancer Gene Census of around 750 genes, which is the definitive list of cancer genes, together with the reference set of mutational signatures and the cell line project. It is run by the Wellcome Sanger Institute and is free for academic users, with a commercial licence for industry. On OnCo it is linked to the term Mutational signature, and the institution record for the Wellcome Sanger Institute points to it.","asOf":"2026-09-04","links":[{"label":"COSMIC (Catalogue of Somatic Mutations in Cancer)","url":"https://cancer.sanger.ac.uk/cosmic"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wellcome-sanger"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://cancer.sanger.ac.uk/cosmic","holds":"The largest curated catalogue of somatic mutations, mutational signatures, and the Cancer Gene Census.","license":"Free academic; commercial licence","maintainer":"Wellcome Sanger Institute"},{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","aka":["CPTAC pipelines","Clinical Proteomic Tumor Analysis Consortium"],"tldr":"CPTAC measures the proteins, not just the genes, of thousands of tumours.","summary":"CPTAC, the Clinical Proteomic Tumor Analysis Consortium, holds proteogenomic data, mass spectrometry proteomics and phosphoproteomics, on tumours linked to TCGA, measuring the proteins rather than just the genes of thousands of tumours. This reveals pathway activity and ADC target abundance that DNA and RNA profiling miss. The consortium is run by the NCI and the data are open. On OnCo it is tied to the technology Proteomics and phosphoproteomics, cited by the bottleneck Data silos and the idea Link single-cell and spatial tumour atlases to clinical outcomes, and referenced by the journal record Cancer Cell and the Drug discovery roadmap.","asOf":"2026-09-04","links":[{"label":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","url":"https://proteomics.cancer.gov"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://proteomics.cancer.gov","holds":"Proteogenomic data (mass spectrometry proteomics and phosphoproteomics) on TCGA-linked tumours.","license":"Open","maintainer":"NCI"},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","aka":[],"tldr":"CSCO guidelines are China's national oncology guidelines, covering about 30 cancers and updated annually. They grade each recommendation by both evidence level and affordability under China's reimbursement list, and they cover Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) years before Western guidelines.","summary":"CSCO guidelines (since 2016 in current form) use a two-dimensional system: evidence level (1A-3) and recommendation grade (I basic, II optional, III) that considers drug accessibility, cost and reimbursement in China's National Reimbursement Drug List. They cover Chinese approvals (toripalimab, camrelizumab, sintilimab, tislelizumab, disitamab vedotin, furmonertinib, savolitinib) years before Western uptake and are published in English for several tumours (e.g. joint CSCO/ASCO NPC guideline 2021). Read with the NMPA approvals list for a view of the world's second-largest oncology market.","asOf":"2026-09-08","links":[{"label":"CSCO (page moved; nearest live section)","url":"https://www.csco.org.cn/"},{"label":"CSCO/ASCO NPC guideline (JCO 2021)","url":"https://doi.org/10.1200/JCO.20.03237"}],"tags":["gap-fill","guidelines"],"related":["nccn","esmo-guidelines","nasopharyngeal","esophageal","hcc","gastric"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab","camrelizumab","tislelizumab","penpulimab"],"companies":[],"institutions":["sysucc","cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.csco.org.cn/","holds":"Chinese Society of Clinical Oncology guidelines for ~30 cancers, graded by evidence and by accessibility/affordability in China (basic vs optional strategies), updated annually.","license":"CSCO","maintainer":"Chinese Society of Clinical Oncology"},{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","aka":["CELLxGENE","CZ CELLxGENE","Human Cell Atlas","HCA","CELLxGENE Census"],"tldr":"CELLxGENE and the Human Cell Atlas hold single-cell data from healthy and diseased tissue, browsable and downloadable.","summary":"CZ CELLxGENE and the Human Cell Atlas hold tens of millions of annotated single cells from healthy and diseased tissue, including tumour microenvironment datasets, all browsable and downloadable. The platform is run by the Chan Zuckerberg Initiative together with the HCA, and the data are released under CC BY. It is the basis for cell-type-level target expression work and immune atlas studies. On OnCo it is linked to the technology Single-cell and spatial profiling, the institutions Chan Zuckerberg Biohub, Max Delbrück Center for Molecular Medicine and Wellcome Sanger Institute, the Virtual cell roadmap and the bottleneck Cold tumours and the immunosuppressive microenvironment, as well as the idea An open foundation model of the cancer cell trained on perturbation data.","asOf":"2026-09-04","links":[{"label":"CZ CELLxGENE / Human Cell Atlas","url":"https://cellxgene.cziscience.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://cellxgene.cziscience.com","holds":"Tens of millions of single cells with annotations, including tumour microenvironment datasets.","license":"CC BY","maintainer":"Chan Zuckerberg Initiative / HCA"},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","aka":["Broad DepMap portal","DepMap portal","Cancer Dependency Map"],"tldr":"Which genes each cancer cell line cannot live without. The map of synthetic-lethal targets.","summary":"DepMap, the Cancer Dependency Map, holds genome-wide CRISPR and drug screens across more than 1,000 cancer cell lines with matched multi-omics, showing which genes each line cannot live without and therefore where synthetic-lethal targets may lie. Its releases include Chronos gene-effect scores, PRISM drug sensitivity data and CCLE omics, published quarterly by the Broad Institute under CC BY 4.0. On OnCo it is linked to the technologies CRISPR functional genomics and Synthetic lethality approaches and to the key paper Defining a Cancer Dependency Map. It is cited by the bottlenecks The undruggable drivers, Lab models that fail to predict what happens in patients, Too many combinations to test and Preclinical results do not reproduce, and by a dozen ideas on screening and model banks.","asOf":"2026-09-04","links":[{"label":"DepMap (Cancer Dependency Map)","url":"https://depmap.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-depmap-tsherniak-cell-2017"],"journals":[],"dependsOn":[],"notes":[],"url":"https://depmap.org","holds":"Genome-wide CRISPR and drug screens across >1,000 cancer cell lines with multi-omics.","license":"CC BY 4.0","maintainer":"Broad Institute"},{"id":"src-dimensions","kind":"collection","name":"Dimensions","aka":[],"tldr":"Dimensions connects papers to the grants and trials behind them.","summary":"Dimensions is a linked research database from Digital Science that connects publications to the grants, clinical trials, patents and policy documents behind them. It updates continuously; a free version is available, with a subscription for analytics. Because it links a paper to its funding and its trials, it answers questions that a plain literature index cannot, such as which grants produced a line of work. On OnCo it is listed as a source with the tags source and data.","asOf":"2026-09-08","links":[{"label":"Dimensions","url":"https://www.dimensions.ai/"}],"tags":["source","data"],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.dimensions.ai/","holds":"Linked research data: publications, grants, trials, patents, policy documents.","license":"Free version; subscription for analytics","maintainer":"Digital Science"},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","aka":[],"tldr":"DrugBank and ChEMBL hold the chemistry and mechanism of every drug and most tool compounds.","summary":"DrugBank and ChEMBL are the two reference databases of drugs and bioactive molecules, with targets, mechanisms and pharmacology, and between them they cover the chemistry and mechanism of every drug and most tool compounds. ChEMBL, run by EMBL-EBI under CC BY-SA, holds more than two million compounds with bioactivities; DrugBank, from the University of Alberta and free for academic use, provides structured drug-target-interaction data. On OnCo the pair is linked to the institution EMBL's European Bioinformatics Institute and cited by the bottlenecks Too many combinations to test and No incentive to repurpose cheap drugs. It also supports ideas such as An open engine that ranks every drug pair by predicted synergy before anyone runs a trial.","asOf":"2026-09-04","links":[{"label":"DrugBank & ChEMBL","url":"https://www.ebi.ac.uk/chembl/"}],"tags":[],"related":["ttd"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.ebi.ac.uk/chembl/","holds":"Drug and bioactive molecule databases with targets, mechanisms, and pharmacology.","license":"ChEMBL CC BY-SA; DrugBank free academic","maintainer":"EMBL-EBI; University of Alberta"},{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","aka":[],"tldr":"The EMA's CHMP highlights show Europe's approval pipeline one month ahead of European Commission decisions.","summary":"The EMA news pages and CHMP meeting highlights hold the monthly CHMP opinions: new medicines recommended, indication extensions and negative opinions. They show Europe's approval pipeline about one month ahead of the European Commission decisions. The highlights are published on the Friday of each CHMP week by the European Medicines Agency and are public. They are best read alongside the FDA OCE approval notifications to see where US and EU decisions diverge. On OnCo the source is tagged source and data, and the institution record European Medicines Agency links to it.","asOf":"2026-09-08","links":[{"label":"EMA news and CHMP meeting highlights","url":"https://www.ema.europa.eu/en/news"}],"tags":["source","data"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ema","fda-oce"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.ema.europa.eu/en/news","holds":"Monthly CHMP opinions: new medicines recommended, indication extensions, negative opinions.","license":"Public","maintainer":"European Medicines Agency"},{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","aka":[],"tldr":"Endpoints News is the fastest read on what biotech and pharma are doing in oncology, deal by deal.","summary":"Endpoints News covers the biopharma industry: deals, readouts, regulatory decisions and executive moves, and it is the fastest read on what biotech and pharma are doing in oncology, deal by deal. It sends daily newsletters and is particularly strong on China-out deals and on ADC and bispecific deal flow. Access is freemium with a premium subscription. On OnCo it is listed as a source with the tags source and news, read for the industry side of oncology.","asOf":"2026-09-08","links":[{"label":"Endpoints News","url":"https://endpoints.news/"}],"tags":["source","news"],"related":["src-biocentury","src-evaluate"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://endpoints.news/","holds":"Biopharma industry news: deals, readouts, regulatory decisions, executive moves.","license":"Freemium; premium subscription","maintainer":"Endpoints News"},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","aka":[],"tldr":"The ESMO guidelines are Europe's treatment algorithms, and the ESMO-MCBS scores how much each new drug actually helps.","summary":"The ESMO Clinical Practice Guidelines are Europe's treatment algorithms, and the accompanying ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) scores how much each new drug actually helps. ESMO-MCBS grades trials A to C in the curative setting and 1 to 5 in the non-curative setting according to the magnitude of benefit. Both are maintained by the European Society for Medical Oncology (ESMO) and are free to read. On OnCo the collection is cited by the bottlenecks Trial design, endpoints and cost, Regulatory divergence between regions, Prices and value, Incentives reward me-too drugs and marginal gains and Toxicity and quality of life are undervalued, and by ideas such as Guidelines list the open trials at every decision point, updated monthly.","asOf":"2026-09-04","links":[{"label":"ESMO Clinical Practice Guidelines & MCBS","url":"https://www.esmo.org/guidelines"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.esmo.org/guidelines","holds":"European treatment guidelines and the Magnitude of Clinical Benefit Scale.","license":"Free","maintainer":"ESMO"},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","aka":[],"tldr":"ESMO Congress, held each October by the European Society for Medical Oncology, is Europe's largest oncology meeting and the autumn counterpart to ASCO, where phase 3 trials now regularly report for the first time. Abstracts are free in Annals of Oncology; other content is for registrants.","summary":"ESMO Congress is Europe's largest oncology congress and the autumn counterpart to ASCO, where phase 3 trials now regularly report for the first time. It is held each October by the European Society for Medical Oncology, with abstracts published in Annals of Oncology; abstracts are free and other content is for registrants. OnCo's readout calendar gives this year's dates and the expected presentations. On OnCo it is tagged source and congress, and the journal record Annals of Oncology links to it.","asOf":"2026-09-08","links":[{"label":"ESMO Congress","url":"https://www.esmo.org/"}],"tags":["source","congress"],"related":["src-asco-meeting-library"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["annals-of-oncology"],"dependsOn":[],"notes":[],"url":"https://www.esmo.org/","holds":"Europe's largest oncology congress; abstracts published in Annals of Oncology.","license":"Abstracts free; content for registrants","maintainer":"European Society for Medical Oncology"},{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","aka":[],"tldr":"The EU Clinical Trials Register and CTIS are Europe's trial registry, complementing ClinicalTrials.gov for EU-only studies.","summary":"The EU Clinical Trials Register and its successor CTIS hold European clinical trial registrations and results, and together they are Europe's trial registry, complementing ClinicalTrials.gov for studies that run only in the EU. The registry is operated by the European Medicines Agency and is public. On OnCo it is linked to the institution European Medicines Agency and is cited by the bottlenecks Trials enrol too few, too slowly, Failures are hidden and Regulatory divergence between regions. It also supports ideas such as Mutual recognition of ethics review across countries, One clinical trial application accepted by regulators in every major region, Actually fine sponsors who do not post trial results and A plain-language summary of every cancer trial result within a year.","asOf":"2026-09-04","links":[{"label":"EU Clinical Trials Register / CTIS","url":"https://euclinicaltrials.eu"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://euclinicaltrials.eu","holds":"European clinical trial registrations and results.","license":"Public","maintainer":"European Medicines Agency"},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","aka":[],"tldr":"Evaluate Vantage forecasts which drugs and modalities will matter commercially in the next decade.","summary":"Evaluate Vantage holds market forecasts, deal analysis and readout scorecards for oncology assets, forecasting which drugs and modalities will matter commercially in the next decade. It is published by Evaluate, part of Norstella, with weekly analysis; the oncology market forecast to 2036 is the reference for investors. Access is freemium, with an Evaluate subscription for the underlying data. On OnCo it is listed as a source with the tags source, news and data.","asOf":"2026-09-08","links":[{"label":"Evaluate Vantage","url":"https://www.evaluate.com/vantage/"}],"tags":["source","news","data"],"related":["src-biocentury"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.evaluate.com/vantage/","holds":"Market forecasts, deal analysis, and readout scorecards for oncology assets.","license":"Freemium; Evaluate subscription for data","maintainer":"Evaluate (Norstella)"},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","aka":[],"tldr":"The FDA's oncology approval notifications are the official record of what is approved for what.","summary":"The FDA's oncology approval notifications are the official record of what is approved for which indication, and this collection holds every oncology approval notification and label together with the FDA's annual list of first-time drug approvals. It is maintained by the US FDA Oncology Center of Excellence and is public domain. OnCo also links the AACR quarterly digests of oncology approvals, and the notifications are best read alongside Project Orbis for international concurrent review. On OnCo the record is cited by bottlenecks including Trial design, endpoints and cost, Wrong doses, Regulatory divergence between regions, Prices and value and Toxicity and quality of life are undervalued, and by the idea Require every oncology candidate to publish how much reaches the brain.","asOf":"2026-09-04","links":[{"label":"Novel Drug Approvals 2026","url":"https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"},{"label":"AACR Q1 2026 digest","url":"https://www.aacr.org/blog/2026/04/01/fda-approvals-in-oncology-january-march-2026/"},{"label":"AACR Q2 2026 digest","url":"https://www.aacr.org/blog/2026/07/02/fda-approvals-in-oncology-april-june-2026/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","holds":"Every oncology approval notification, label, and the annual novel drug list.","license":"Public domain","maintainer":"US FDA Oncology Center of Excellence"},{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","aka":[],"tldr":"Fierce Biotech is where trial failures get reported plainly.","summary":"Fierce Biotech is industry news with a dedicated oncology channel, covering trial failures and successes, layoffs and financings, and it is where trial failures get reported plainly. It is published daily by Questex and is free with registration. Because it reports the failures as directly as the successes, it is a useful counterweight to company announcements and to news outlets that lead only with positive readouts. On OnCo it is listed as a source with the tags source and news, read for the industry side of oncology.","asOf":"2026-09-08","links":[{"label":"Fierce Biotech","url":"https://www.fiercebiotech.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.fiercebiotech.com/","holds":"Industry news with an oncology channel: trial failures and successes, layoffs, financings.","license":"Free with registration","maintainer":"Questex"},{"id":"first-descents","kind":"collection","name":"First Descents","aka":[],"tldr":"First Descents takes young adults with cancer on free week-long outdoor adventures, with the travel paid for too.","summary":"First Descents runs week-long kayaking, climbing and surfing programmes for young adults with cancer, and for those living with other serious illnesses, at no cost. Adolescents and young adults are the group most under-served by cancer support, and the programmes are built around peer connection as much as adventure. Travel scholarships cover getting there.","asOf":"2026-09-17","links":[{"label":"First Descents","url":"https://firstdescents.org/"}],"tags":["free","patient-org"],"related":["maggies-centres","penny-brohn-uk","livestrong-at-the-ymca","look-good-feel-better","imerman-angels","kesem"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://firstdescents.org/","holds":"Free outdoor adventure programmes (kayaking, climbing, surfing) for young adults aged 18 to 39 with cancer and other serious conditions, including travel scholarships, in the United States.","maintainer":"First Descents"},{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","aka":[],"tldr":"Real-world evidence at scale: what happened to patients with a given genomic profile on a given treatment.","summary":"The Flatiron Health and Foundation Medicine Clinico-Genomic Database is real-world evidence at scale: it records what happened to patients with a given genomic profile on a given treatment. It links electronic health record outcomes with comprehensive genomic profiles for more than 100,000 US cancer patients and is used for external control arms, label expansions and training multimodal outcome models. Access is commercial or by research agreement, and the database is maintained by Flatiron Health, part of Roche, with Foundation Medicine, so the company records for Foundation Medicine (Roche) and Roche / Genentech are linked. The collection is referenced by the roadmaps on AI in the oncology clinic, AI in oncology and trial modernisation.","asOf":"2026-09-08","links":[{"label":"Flatiron Health and Foundation Medicine Clinico-Genomic Database (page moved; nearest live section)","url":"https://flatiron.com/"}],"tags":["data","real-world"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["foundation-medicine","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://flatiron.com/","holds":"Linked EHR outcomes and comprehensive genomic profiles for >100,000 US cancer patients.","license":"Commercial / research access","maintainer":"Flatiron Health (Roche) and Foundation Medicine"},{"id":"force-facing-our-risk","kind":"collection","name":"FORCE: Facing Our Risk of Cancer Empowered","aka":[],"tldr":"FORCE gives free information, a helpline and peer navigators to anyone facing an inherited cancer risk such as a BRCA or Lynch syndrome gene change.","summary":"FORCE is the largest US organisation for people affected by hereditary cancer. Its peer navigation programme matches people with a trained volunteer who has faced the same gene change and decisions; its helpline and expert-reviewed pages explain testing, surveillance, risk-reducing surgery and trials in plain language; and it runs support groups and an annual conference. Services are free and open to anyone, and its content is used internationally.","asOf":"2026-09-17","links":[{"label":"FORCE: Facing Our Risk of Cancer Empowered","url":"https://www.facingourrisk.org/"}],"tags":["free","patient-org"],"related":["sharsheret"],"cancers":[],"sections":[],"technologies":["germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hereditary-cancer-syndromes","lynch-syndrome"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.facingourrisk.org/","holds":"Free helpline, peer navigation, expert-reviewed information and support groups for people with hereditary cancer risk (BRCA, Lynch syndrome and other inherited syndromes), including help understanding test results and options.","maintainer":"FORCE"},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","aka":[],"tldr":"Gavi pays for HPV vaccine in lower-income countries so national programmes can give it to girls for free, where cervical cancer kills most.","summary":"Most cervical cancer deaths happen in low- and middle-income countries with little screening, which makes vaccination the most effective tool available. Gavi co-finances HPV vaccine introduction and supply for eligible countries and, since the shift to a single-dose schedule endorsed by the WHO, has been able to reach far more girls with the same doses. The programme page lists supported countries and progress. For a family in a supported country, the vaccine is free through the national immunisation programme.","asOf":"2026-09-17","links":[{"label":"Gavi HPV vaccine support","url":"https://www.gavi.org/types-support/vaccine-support/human-papillomavirus"}],"tags":["free","public"],"related":["nhs-hpv-vaccination","us-vaccines-for-children"],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["who"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.gavi.org/types-support/vaccine-support/human-papillomavirus","holds":"Financing and supply of HPV vaccine for national programmes in lower-income countries, so that girls can be vaccinated free through their health system; the page lists the countries supported and how the programme has grown.","maintainer":"Gavi, the Vaccine Alliance"},{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","aka":[],"tldr":"GLOBOCAN is the world's cancer numbers: incidence and mortality estimates for 185 countries and 36 cancers.","summary":"GLOBOCAN, presented through the Global Cancer Observatory, provides the world's cancer numbers: incidence and cancer death estimates for 185 countries and 36 cancers. It is produced by the International Agency for Research on Cancer (IARC / WHO) and is free to use. The observatory is organised into Cancer Today for current estimates, Cancer Tomorrow for projections and Cancer Over Time for trends. On OnCo it is cited by the bottlenecks The hardest cancers are found late, Prevention we already have is not deployed, Most of the world has almost no cancer care and Funding follows fashion, not burden, and by ideas such as A public map of trial deserts to steer where new sites open and Make a population cancer registry a condition of every cancer aid programme.","asOf":"2026-09-04","links":[{"label":"GLOBOCAN / Global Cancer Observatory","url":"https://gco.iarc.who.int"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["asian-pacific-journal-of-cancer-prevention","cancer-causes-and-control","cancer-epidemiology","cancer-epidemiology-biomarkers-prevention"],"dependsOn":[],"notes":[],"url":"https://gco.iarc.who.int","holds":"Global cancer incidence and mortality estimates for 185 countries and 36 cancers.","license":"Free","maintainer":"IARC / WHO"},{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","aka":[],"tldr":"Healio Hematology/Oncology publishes clinician-facing daily news with good approval and lifestyle-risk coverage.","summary":"Healio Hematology/Oncology publishes clinician-facing daily news and expert Q&As across haematology and oncology, with good coverage of approvals and of lifestyle-related cancer risk. It is run by Healio and SLACK and is free with registration. It publishes daily, so it functions as a running feed rather than a periodical. On OnCo it is listed as a source with the tags source and news, one of the clinician-facing daily feeds OnCo reads for approval news and for the expert question-and-answer pieces.","asOf":"2026-09-08","links":[{"label":"Healio Hematology/Oncology","url":"https://www.healio.com/news/hematology-oncology"}],"tags":["source","news"],"related":["src-medscape-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.healio.com/news/hematology-oncology","holds":"Daily news and expert Q&As across haematology and oncology.","license":"Free with registration","maintainer":"Healio / SLACK"},{"id":"hpa","kind":"collection","name":"Human Protein Atlas","aka":[],"tldr":"The Human Protein Atlas shows where in the body each protein is found, which tells you whether an ADC target is safe.","summary":"The Human Protein Atlas maps protein expression across normal and cancer tissues by immunohistochemistry, complemented by single-cell and subcellular atlases, so a reader can see where in the body each protein is found and therefore whether an ADC target is likely to be safe. Its pathology atlas includes survival correlations, and the resource is essential for target expression screening. It is run by KTH and Uppsala and released under CC BY-SA. On OnCo it is linked to the technologies Antibody-drug conjugate (ADC) and Proteomics and phosphoproteomics, and it is cited by the bottleneck Preclinical results do not reproduce and by the idea Only use antibodies proven to hit their target with knockout controls.","asOf":"2026-09-04","links":[{"label":"Human Protein Atlas","url":"https://www.proteinatlas.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc","proteomics"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.proteinatlas.org","holds":"Protein expression across normal and cancer tissues by IHC, plus single-cell and subcellular atlases.","license":"CC BY-SA 3.0","maintainer":"KTH / Uppsala"},{"id":"imerman-angels","kind":"collection","name":"Imerman Angels","aka":[],"tldr":"Imerman Angels matches you free with someone who has been through the same cancer, so you can talk to a person who understands.","summary":"Founded by a young testicular cancer survivor, Imerman Angels matches patients, survivors, previvors and carers with a trained volunteer who has faced the same diagnosis, matching on cancer type, age and situation. Matches are made anywhere in the world and the service is free. Peer support of this kind is one of the interventions people with cancer rate most highly.","asOf":"2026-09-17","links":[{"label":"Imerman Angels","url":"https://imermanangels.org/"}],"tags":["free","patient-org"],"related":["maggies-centres","penny-brohn-uk","livestrong-at-the-ymca","look-good-feel-better","first-descents","kesem"],"cancers":[],"sections":[],"technologies":["psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://imermanangels.org/","holds":"Free one-to-one peer mentoring: anyone with cancer, a survivor or a carer is matched with a Mentor Angel who has had the same cancer, at a similar age, anywhere in the world.","maintainer":"Imerman Angels"},{"id":"ighg","kind":"collection","name":"International Guideline Harmonization Group for late effects of childhood cancer","aka":["IGHG","International Late Effects of Childhood Cancer Guideline Harmonization Group"],"tldr":"Three countries wrote three different sets of follow-up rules for the same survivors, and the rules disagreed about who to screen, how and how often. Since 2010 this group has been settling those disagreements one organ at a time, in public, with the evidence graded and the disagreement named.","summary":"The problem the group was formed to solve is stated in each of its papers: surveillance recommendations \"vary considerably\" between the existing long-term follow-up guidelines, which \"impedes the implementation of screening\". A survivor of the same treatment could be told to have a yearly echocardiogram in one country, one every five years in another, and nothing in a third. The International Late Effects of Childhood Cancer Guideline Harmonization Group was initiated in 2010 with the aim of establishing \"a common vision and integrated strategy for the surveillance of late effects in childhood and young adult cancer survivors\".\n\nThe method is consistent across topics: an international multidisciplinary panel, a systematic review of the evidence for the late effect and for the surveillance test, grading of each recommendation by the strength of the underlying evidence and the potential benefit from early detection, and transparent reporting of where the panel had to rely on consensus. Panels have run from 25 to 33 experts across as many as ten countries, often jointly with PanCare.\n\nThe published topics include cardiomyopathy surveillance (2015), breast cancer surveillance after chest radiation (2013), premature ovarian insufficiency (2016), male gonadotoxicity (2017), thyroid cancer (2018), ototoxicity (2019) and fertility preservation for female and male patients (2021), alongside recommendations on bone mineral density, central nervous system neoplasms, coronary artery disease, dexrazoxane cardioprotection, education and employment, fatigue, hepatic toxicity, hypothalamic-pituitary dysfunction, mental health, metabolic syndrome, nephrotoxicity, obstetric care and pulmonary dysfunction, and anthracycline dose equivalence ratios. The group's site also lists topics still in development, among them colorectal cancer, dyslipidaemia, growth hormone treatment, neurocognitive problems, osteonecrosis, overweight and obesity, splenic dysfunction, thyroid dysfunction and underweight.\n\nTwo honest features are worth a reader's attention. The guidelines frequently conclude that the evidence is thin: the male gonadotoxicity paper states that the recommendations \"reveal the paucity of high-quality evidence, highlighting the need for further targeted research\". And where two screening strategies are equally unproven, the group says so rather than choosing: for thyroid cancer, \"Of the two available surveillance strategies, thyroid ultrasound and neck palpation, neither was shown to be superior\", so the panel produced a decision aid for a shared decision rather than a recommendation to screen.","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Late_effect","links":[{"label":"International Guideline Harmonization Group: published and in-development guidelines","url":"https://www.ighg.org/guidelines/"},{"label":"A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors (Pediatr Blood Cancer 2013)","url":"https://doi.org/10.1002/pbc.24445"},{"label":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer (IGHG) (Lancet Oncol 2015)","url":"https://doi.org/10.1016/S1470-2045(14)70409-7"},{"label":"Recommendations for breast cancer surveillance for female survivors given chest radiation (IGHG) (Lancet Oncol 2013)","url":"https://doi.org/10.1016/S1470-2045(13)70303-6"},{"label":"Recommendations for ototoxicity surveillance for childhood, adolescent and young adult cancer survivors (IGHG with PanCare) (Lancet Oncol 2019)","url":"https://doi.org/10.1016/S1470-2045(18)30858-1"},{"label":"Recommendations for gonadotoxicity surveillance in male childhood, adolescent and young adult cancer survivors (IGHG with PanCareSurFup) (Lancet Oncol 2017)","url":"https://doi.org/10.1016/S1470-2045(17)30026-8"},{"label":"Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer (IGHG with PanCareSurFup) (Cancer Treat Rev 2018)","url":"https://doi.org/10.1016/j.ctrv.2017.11.005"}],"tags":["rejuvenation","survivorship","paediatric","late-effects","guideline"],"related":["rejuv-paed-cog-ltfu-guidelines","rejuv-paed-uk-long-term-follow-up","pancaresurfup","survivorship-care-plan"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-care-fragmentation","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The group harmonises surveillance, not treatment. What to do about a late effect once found is left to the relevant specialty."],"url":"https://www.ighg.org/guidelines/","holds":"Harmonised, evidence-graded surveillance recommendations for the late effects of childhood, adolescent and young adult cancer, each developed by an international multidisciplinary panel.","license":"Published in the peer-reviewed literature; summaries free on the group's site","maintainer":"International Guideline Harmonization Group, with PanCare and the Children's Oncology Group"},{"id":"intogen","kind":"collection","name":"IntOGen","aka":[],"tldr":"IntOGen reads the mutations in thousands of tumour genomes and asks which genes are hit more often, or in more telling patterns, than chance allows. Those are its driver genes, and it says for each whether the mutations switch the gene on or knock it out.","summary":"IntOGen (Integrative OncoGenomics) runs several driver-discovery methods (dNdScv, OncodriveFML, OncodriveCLUSTL, HotMAPS, smRegions, CBaSE, MutPanning) over sequenced tumour cohorts from TCGA, ICGC, cBioPortal and other public sources, combines their results and publishes a Compendium of Cancer Genes: each row a gene, a cohort, the methods that called it, the share of samples mutated and a role (Act for activating, LoF for loss-of-function). The 2024-09-20 release ships under CC0 1.0 and feeds the driver roles and the cohort-driver evidence tier on OnCo's gene pages, which list the genes it calls.","asOf":"2026-09-04","links":[{"label":"IntOGen","url":"https://www.intogen.org"}],"tags":[],"related":["civic","open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":["ctnnb1","ccnd1","tert","pole","apc","fgfr4","pold1","nrg1","tsc1","mycn","setd2","tsc2","pml","kif5b","smad2","jak3","ccdc6","epha3","epha7","hdac4","prkcb","prkd1","irak1","arnt","pdcd1lg2","prkcd","col6a3","tec","vhl","pten","atm","cdkn2a","h3-3a","notch1","smad4","dicer1","rb1","hras","smarcb1","smarca4","stk11","bap1","arid1a","ercc2","kmt2d","runx1","palb2","wt1","cebpa","fbxw7","chek2","cdh1","bcor","atrx","gnas","sf3b1","asxl1","etv6","cbl","pik3r1","kmt2c","kdm6a","pbrm1","pms2","crebbp","nfe2l2","ep300","cdk12","bard1","lrp1b","mapk1","flcn","srsf2","spop","u2af1","myc-gene","setbp1","gata2","map3k1","casp8","gnaq","sdha","fbxo11","cdkn1b","pik3cb","nf2","fat1","ppp2r1a","smad3","ccnd2","keap1","stag2","sh2b3","rad50","prkar1a","notch2","rac1","gna11","foxa1","sos1","pot1","mecom","fanca","h3c2","plcg1","arhgap35","arid2","map2k4","stat3","lztr1","ctcf","rhoa","arid1b","gata3","drosha","hgf","bcl11a","rasa1","b2m","kdm5c","cic","cdkn1a","fhit","foxp1","rras2","araf","etv1","rpl5","pax5","spen","grin2a","ptprb","ebf1","pim1","prex2","hsp90aa1","cacna1d","ptprt","fubp1","foxo1","il7r","erg","ercc3","sufu","prdm1","ubr5","klf5","slc34a2","ddx3x","klf4","card11","tet1","cblb","ccnd3","ikbkb","tbl1xr1","bcl10","abl2","etv5","etv4","crlf2","fcgr2b","atp1a1","cdx2","gsk3b","myd88","birc6","btg1","nsd2","ciita","birc3","bcl6","rpl10","nfkbie","atg7","rpl22","zrsr2","tgfbr1","pcbp1","fas","tnfaip3","tnfrsf14","p2ry8","dcc","stat6","eif1ax","aldh2","cul3","hla-b","zfp36l1","socs1","zeb1","ptprd","sgk1","foxl2","map2k7","gna13","tnc","mef2b","bcl7a","kmt2b","sin3a","gnai2","hla-c","smarca2","setd1b","btg2","tmsb4x","id3","mga","nfkbia","pou2f2","ptpn6","tfap4","cd58","cysltr2","klhl6","usp7","dtx1","sp140","ube2a","tgfbr2","axin1","cdc73","rnf43","amer1","tcf7l2","cux1","hnf1a","zfhx3","ppm1d","tbx3","tp63","maml2","suz12","recql4","trim24","ranbp2","klf6","acvr1b","bmpr1a","ncor1","acvr2a","cltc","rbm10","nkx2-1","qki","fat4","snd1","chd4","trrap","tmprss2","myh9","cbfb","max","usp6","hip1","nsd1","cdh11","daxx","cyld","tfg","rspo2","bcl11b","lats1","six1","bcl9l","rad21","prdm16","ncor2","maf","ptprk","tent5c","zbtb16","phf6","msi2","tpr","med12","bcorl1","ppp6c","ncoa2","zmym2","runx1t1","znf521","plag1","lats2","psip1","sall4","rap1b","ackr3","sox9","akap9","rap1gds1","kat6b","polq","ctnna1","csmd3","il6st","cdkn2c","cntrl","cnot3","trip11","aff4","ptpn13","crtc1","ptprc","col1a1","kat6a","afdn","clip1","nutm1","knl1","irf1","bcl9","elf4","usp8","nbea","arhgef12","ddb2","camta1","aff3","ell","foxo3","atp2b3","wwtr1","flg","ddx6","cltcl1","nsd3","nfatc2","eif3e","lef1","irs4","hnrnpa2b1","fus","nfkb2","nup98","pcm1","fcrl4","lrig3","trim33","rest","znf331","eps15","elk4","kdm5a","ing1","zmym3","tcl1a","rhpn2","malt1","elf3","tal2","traf7","was","nup214","hoxc13","pabpc1","tal1","lifr","msn","brd7","acsl3","mllt1","atf7ip","asxl2","znrf3","ptpn14","rps6ka3","lpa","h4c9","adamts9","znf750","rnf6","ncoa1","rbfox1","fmn2","myeov","znf429","gpc5","baz1a","mllt3","aff1","fat3","robo2","ctnna2","rnf213","myh11","fam135b","fbln2","setdb1","ank1","arhgap5","chd2","ctnnd2","usp9x","cdh10","rgs7","bclaf1","sirpa","arhgef10","dcaf12l2","dgcr8","mb21d2","myo5a","naca","wnk2","cd209","fam174b","grm3","ldb1","muc6","n4bp2","nin","parp4","prdm2","rgpd3","arhgef10l","cnot9","cyp2c8","dot1l","dusp16","eln","foxa2","kdm3b","mllt6","nipbl","numa1","nxf1","smarcd1","smc1a","snx29","taf15","tcf12","tcf4","tfrc","abcc4","acsl6","acsm3","ajuba","alpk1","ankrd11","bmp6","cadm2","cant1","casz1","ccar1","ccnt1","ccr7","cep89","chd7","chrdl1","cmtr2","col2a1","col6a6","cpeb3","cspg4","dhx9","dis3","dsp","eftud2","egr2","eif4a2","esrra","fat2","fbn2","fgd1","fgd5","fndc3b","gli1","gmps","gpaa1","gtf2i","hcar3","hla-dqa1","hsp90ab1","hspg2","inppl1","itgav","kat7","kmt5a","knstrn","lsm14a","macc1","mark2","mcm7","mdga2","med23","mib2","ncaph","nckipsd","nktr","nprl2","nrk","nt5c3a","nutm2d","nvl","pcmtd1","pdzd2","peg3","per3","pi4ka","picalm","plxnc1","ppp3ca","prkd2","prune2","pspc1","ptma","ptpn3","pwwp2a","rasa2","rbm15","rbm38","rbm39","rela","ripk1","rps3a","rragc","rrn3","samhd1","sdcbp","shtn1","sox17","sox21","srgap3","susd2","taf1l","tgif1","thrap3","traf3","trim49c","tyw2","u2af2","ubxn11","vav1","wnt1","zbtb20","zbtb48","zbtb7b","zcchc8","zcrb1","znf208","znf274","znf395","znf626","znf680","znf721","znf780a","znf814","znf90","znf93","zxdb"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OnCo uses only the current CC0 release; the pre-2019 archives on the download page carry a CC BY-NC 4.0 licence and are not read.","Cancer type codes follow OncoTree-style acronyms (BRCA, LUAD, COADREAD); the cohorts table gives their names."],"url":"https://www.intogen.org","holds":"Catalogue of cancer driver genes called by mutation analysis of tumour cohorts, with an activating or loss-of-function role per gene and cohort.","license":"CC0 1.0 (current driver catalogue; archives before 2019 are CC BY-NC 4.0)","maintainer":"Barcelona Biomedical Genomics Lab, IRB Barcelona"},{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","aka":[],"tldr":"In Ireland, BowelScreen, BreastCheck and CervicalCheck are free. You register once and get invited by age.","summary":"The HSE National Screening Service runs Ireland's population screening: BowelScreen (a home FIT kit), BreastCheck (mammography) and CervicalCheck (HPV primary screening), each free and invitation-based, with eligibility by age set out on the programme websites. People who are not on the register can add themselves online. The Irish Cancer Society Support Line answers questions about screening and results.","asOf":"2026-09-17","links":[{"label":"Ireland's National Screening Service","url":"https://www.screeningservice.ie/"}],"tags":["free","public"],"related":["nhs-cancer-screening-programmes","australia-cancer-screening-programs","nz-time-to-screen","cdc-nbccedp"],"cancers":["colorectal","breast-cancer","cervical"],"sections":[],"technologies":["colorectal-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.screeningservice.ie/","holds":"BowelScreen, BreastCheck and CervicalCheck: Ireland's free national cancer screening programmes, with the current age ranges and how to register on each programme's site.","maintainer":"Health Service Executive (HSE)"},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","aka":[],"tldr":"The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA.","summary":"Japanese organ societies publish some of the most detailed surgical and endoscopic guidelines in oncology (JGCA gastric cancer treatment guidelines, 6th edition 2021; Japan Esophageal Society; JSH hepatocellular carcinoma), reflecting trials such as JCOG9501, ACTS-GC, SPIRITS and JCOG1109. Drug availability differs (S-1, nedaplatin, TAS-102 origin), and PMDA approvals sometimes precede FDA (e.g. entrectinib, nivolumab for gastric cancer, cabozantinib-nivolumab). JSMO's clinical guidance on comprehensive genomic profiling underpins Japan's national reimbursement of CGP panels (2019).","asOf":"2026-09-08","links":[{"label":"JSMO","url":"https://www.jsmo.or.jp/en/"},{"label":"JGCA guidelines 2021 (Gastric Cancer)","url":"https://doi.org/10.1007/s10120-022-01331-8"}],"tags":["gap-fill","guidelines"],"related":["gastric","esophageal","hcc","cholangiocarcinoma","endoscopic-resection","cgp"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["jcog"],"institutions":["ncc-japan","jfcr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-clinical-oncology"],"dependsOn":[],"notes":[],"url":"https://www.jsmo.or.jp/en/","holds":"Japanese Society of Medical Oncology and Japan Society of Clinical Oncology guidelines; organ-specific societies (JGCA gastric, JSHBPS, JLCS lung, JBCS breast) publish detailed guidelines many translated into English; the JSMO/JSCO/JCA joint guideline on tumour-agnostic testing.","license":"Society terms","maintainer":"JSMO / JSCO"},{"id":"kesem","kind":"collection","name":"Kesem","aka":[],"tldr":"Kesem runs free summer camps for children whose mum or dad has cancer, staffed by college student volunteers across the US.","summary":"Children of parents with cancer carry a burden that cancer services rarely address. Kesem, which began as Camp Kesem at Stanford, runs free week-long summer camps and year-round activities for these children through university chapters nationwide, staffed by trained student volunteers. Camps are free to families and funded by donations.","asOf":"2026-09-17","links":[{"label":"Kesem","url":"https://www.kesem.org/"}],"tags":["free","patient-org"],"related":["maggies-centres","penny-brohn-uk","livestrong-at-the-ymca","look-good-feel-better","imerman-angels","first-descents"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.kesem.org/","holds":"Free summer camps and year-round support for children aged 6 to 18 whose parent has, or has had, cancer, run by college student volunteers at chapters across the United States.","maintainer":"Kesem"},{"id":"knitted-knockers","kind":"collection","name":"Knitted Knockers","aka":[],"tldr":"Knitted Knockers posts free soft knitted breast prostheses to anyone who has had breast surgery, made by volunteer knitters.","summary":"Knitted Knockers are soft, light breast prostheses knitted by volunteers to a published pattern. They can be worn soon after surgery when silicone prostheses are too heavy or the scar is tender, and can be adjusted or fitted with a nipple. The foundation posts them free on request in the US and affiliated groups do the same in other countries; the pattern is free for any knitter.","asOf":"2026-09-17","links":[{"label":"Knitted Knockers","url":"https://www.knittedknockers.org/"}],"tags":["free","patient-org"],"related":["little-princess-trust","wigs-for-kids"],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mastectomy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.knittedknockers.org/","holds":"Free handmade, soft knitted breast prostheses for women who have had a mastectomy or lumpectomy, made by volunteers and posted on request, with the pattern published for knitting groups worldwide.","maintainer":"Knitted Knockers Support Foundation"},{"id":"krebsinformationsdienst","kind":"collection","name":"Krebsinformationsdienst (KID)","aka":[],"tldr":"In Germany, the DKFZ's Krebsinformationsdienst answers questions about cancer free on 0800 420 30 40, every day, staffed by doctors.","summary":"The Krebsinformationsdienst is the German Cancer Research Center's public information service, funded by the federal and Baden-Wuerttemberg governments. Doctors answer questions by phone and email in German, and the website carries detailed, referenced information on cancers, treatments, trials and living with cancer. It is free and independent of industry, and it is the German equivalent of the NCI Cancer Information Service.","asOf":"2026-09-17","links":[{"label":"Krebsinformationsdienst (KID)","url":"https://www.krebsinformationsdienst.de/"}],"tags":["free","helpline"],"related":["nci-cancer-information-service","macmillan-support-line","cruk-nurse-helpline","acs-cancer-helpline","cancercare","cancer-support-community","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.krebsinformationsdienst.de/","holds":"Germany's free cancer information service from the DKFZ: a free phone line (0800 420 30 40, every day) and email service staffed by doctors, plus evidence-based information in German on every cancer.","maintainer":"German Cancer Research Center (DKFZ)"},{"id":"lazarex-cancer-foundation","kind":"collection","name":"Lazarex Cancer Foundation","aka":[],"tldr":"Lazarex pays the travel and lodging costs that stop people joining cancer trials in the US, and helps them find a trial in the first place.","summary":"Clinical trials supply the study drug and trial-related tests free, but travel and time away from work fall on the patient and are the reason many people, especially those on low incomes, never enrol. Lazarex reimburses those out-of-pocket costs for patients and a companion for the duration of the trial, with income-based eligibility, and runs programmes with cancer centres to improve access for under-represented communities. Applications go through the foundation's website.","asOf":"2026-09-17","links":[{"label":"Lazarex Cancer Foundation","url":"https://lazarex.org/"}],"tags":["free","patient-programme"],"related":["clinicaltrials-gov","nihr-be-part-of-research"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["financial-toxicity"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://lazarex.org/","holds":"Reimbursement of travel, lodging and related costs for patients and a companion taking part in FDA clinical trials in the United States, plus help identifying trials, so that cost does not decide who can enrol.","maintainer":"Lazarex Cancer Foundation"},{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","aka":[],"tldr":"The Leukemia & Lymphoma Society is the main US blood-cancer charity, unusual for running its own precision-medicine trials (Beat AML, PedAL) and investing directly in biotech, alongside co-pay assistance and one-to-one information specialists.","summary":"Founded 1949. LLS funds ~$1.7 billion in research to date, runs Beat AML (genomic-assignment master trial that showed rapid genomic testing is feasible in AML, Nat Med 2020) and the paediatric PedAL/LLS Dare to Dream project, offers Information Specialists, the Clinical Trial Support Center (nurse navigators), co-pay assistance (>$500 million distributed), and advocacy on drug costs and oral parity. Its patient booklets cover every leukaemia, lymphoma, myeloma and MDS/MPN.","asOf":"2026-09-08","links":[{"label":"LLS","url":"https://www.lls.org/"},{"label":"Beat AML (Nat Med 2020)","url":"https://doi.org/10.1038/s41591-020-1089-8"}],"tags":["gap-fill","patient-org"],"related":["aml","all-leukemia","cll","cml","dlbcl","follicular-lymphoma","mantle-cell-lymphoma","hodgkin-lymphoma","multiple-myeloma","mds","myeloproliferative-neoplasms"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lls-therapy-acceleration-program"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-burd-nat-med"],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.lls.org/","holds":"Patient education and information specialists for blood cancers, co-pay and travel assistance programmes, the Beat AML and PedAL master trials, Therapy Acceleration Program venture funding, and clinical trial navigation.","license":"Copyright LLS","maintainer":"LLS"},{"id":"livestrong-at-the-ymca","kind":"collection","name":"LIVESTRONG at the YMCA","aka":[],"tldr":"LIVESTRONG at the YMCA is a free twelve-week exercise programme for adults who have had cancer, run at YMCAs across the US.","summary":"Exercise after cancer treatment improves fitness, fatigue and quality of life, and structured programmes are now recommended in guidelines. LIVESTRONG at the YMCA delivers one: adult survivors meet twice a week for twelve weeks with instructors trained in cancer exercise, and participants get a Y membership for the programme. It is free at participating YMCAs and the Livestrong site lists locations.","asOf":"2026-09-17","links":[{"label":"LIVESTRONG at the YMCA","url":"https://www.livestrong.org/"}],"tags":["free","patient-programme"],"related":["maggies-centres","penny-brohn-uk","look-good-feel-better","imerman-angels","first-descents","kesem"],"cancers":[],"sections":[],"technologies":["structured-exercise-survivorship","exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.livestrong.org/","holds":"A free twelve-week small-group exercise programme for adult cancer survivors at participating YMCAs in the United States, led by trained instructors, with a YMCA membership included for the duration.","maintainer":"Livestrong Foundation and YMCA of the USA"},{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","aka":[],"tldr":"Congress results translated for people with breast cancer, fast and accurately.","summary":"Living Beyond Breast Cancer publishes patient-facing breast cancer news, congress summaries and question guides, translating congress results for people with breast cancer quickly and accurately. Its ASCO and SABCS summaries are among the best patient-facing trial explainers, and the question guides help patients prepare for appointments. It is maintained by Living Beyond Breast Cancer and is free. On OnCo it is tagged source and patient, and the collection Susan G. Komen links to it.","asOf":"2026-09-08","links":[{"label":"Living Beyond Breast Cancer","url":"https://www.lbbc.org/news"}],"tags":["source","patient"],"related":["src-sabcs","src-asco-meeting-library"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.lbbc.org/news","holds":"Patient-facing breast cancer news, congress summaries, and question guides.","license":"Free","maintainer":"Living Beyond Breast Cancer"},{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","aka":[],"tldr":"Look Good Feel Better runs free workshops that teach people having cancer treatment how to manage skin, brow and hair changes, with a free product kit.","summary":"Look Good Feel Better began in the US in 1989 and now runs in more than twenty countries, in the UK as a separate charity. Volunteer beauty professionals run free group workshops, in hospitals, centres and online, covering skincare during treatment, drawing brows, managing lashes, and wigs and head coverings, and participants receive a kit of donated products. It is open to anyone with cancer, without referral.","asOf":"2026-09-17","links":[{"label":"Look Good Feel Better","url":"https://lookgoodfeelbetter.org/"},{"label":"Look Good Feel Better UK","url":"https://lookgoodfeelbetter.co.uk/"}],"tags":["free","patient-programme"],"related":["maggies-centres","penny-brohn-uk","livestrong-at-the-ymca","imerman-angels","first-descents","kesem"],"cancers":[],"sections":["rejuvenation"],"technologies":["wigs-cranial-prosthesis","scalp-cooling"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://lookgoodfeelbetter.org/","holds":"Free skincare and make-up workshops, in person and online, for people dealing with the visible effects of cancer treatment, with a free kit of donated products; run in the US, the UK and many other countries.","maintainer":"Look Good Feel Better (US) and Look Good Feel Better UK"},{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","aka":[],"tldr":"LUNGevity is the largest US lung cancer charity, focused on making sure every patient gets comprehensive biomarker testing and access to targeted therapy and trials, with a screening-advocacy partner in GO2.","summary":"LUNGevity (founded 2001) runs 'No One Missed' biomarker testing campaigns, patient education for each driver (EGFR, ALK, ROS1, KRAS G12C, MET, RET, HER2, NTRK, BRAF), the Lung Cancer Registry patient-reported research platform, HOPE Summits for survivors, and translational research awards. GO2 for Lung Cancer (Bonnie J. Addario Lung Cancer Foundation + Lung Cancer Alliance) runs the Centers of Excellence network for screening and care. Driver-specific patient groups (ALK Positive, EGFR Resisters, ROS1ders, KRAS Kickers, MET Crusaders) have become influential research partners.","asOf":"2026-09-08","links":[{"label":"LUNGevity","url":"https://www.lungevity.org/"},{"label":"GO2 for Lung Cancer","url":"https://go2.org/"},{"label":"ALK Positive","url":"https://www.alkpositive.org/"}],"tags":["gap-fill","patient-org"],"related":["nsclc","sclc","low-dose-ct-screening","egfr","alk","kras","ros1","cgp"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["companion-diagnostic-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.lungevity.org/","holds":"Biomarker testing education, the Lung Cancer HELPLine, patient-facing trial finder, survivorship programmes, research awards, and the Lung Cancer Registry; GO2 runs the Centers of Excellence and screening advocacy.","license":"Copyright LUNGevity","maintainer":"LUNGevity Foundation"},{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","aka":[],"tldr":"The Lymphoma Research Foundation is the largest US lymphoma-specific charity, with plain-language guides for over 20 lymphoma subtypes and a research programme focused on mantle cell and adolescent/young adult lymphoma.","summary":"Formed 2001 by merger. Provides subtype-level patient education (DLBCL, FL, MCL, MZL, Hodgkin, T-cell, CNS, Waldenström), a helpline staffed by health educators, a trial-finder, and the Mantle Cell Lymphoma Consortium which has convened MCL researchers since 2003 and helped define the field's research agenda. Also funds Career Development Awards and the Lymphoma Scientific Research Mentoring Program.","asOf":"2026-09-08","links":[{"label":"LRF","url":"https://lymphoma.org/"}],"tags":["gap-fill","patient-org"],"related":["dlbcl","follicular-lymphoma","mantle-cell-lymphoma","hodgkin-lymphoma","peripheral-t-cell-lymphoma","primary-cns-lymphoma","waldenstrom"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://lymphoma.org/","holds":"Disease-specific guides for every lymphoma subtype, the Lymphoma Helpline and clinical trial finder, the Focus on Lymphoma app, research grants and the Mantle Cell Lymphoma Consortium.","license":"Copyright LRF","maintainer":"LRF"},{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","aka":[],"tldr":"Macmillan Cancer Support covers the practical side of cancer: money, work, coping, and where to get help.","summary":"Macmillan Cancer Support provides practical, emotional and financial support information for people with cancer in the UK, covering money, work, coping and where to get help. The information is continuously updated by Macmillan Cancer Support and is free. It covers the practical side of cancer that clinical sources leave out, from benefits and employment to coping and support services. On OnCo it is tagged source and patient, and the institution record Macmillan Cancer Support links to it.","asOf":"2026-09-08","links":[{"label":"Macmillan Cancer Support","url":"https://www.macmillan.org.uk/cancer-information-and-support"}],"tags":["source","patient"],"related":["src-cruk-about-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.macmillan.org.uk/cancer-information-and-support","holds":"Practical, emotional, and financial support information for people with cancer in the UK.","license":"Free","maintainer":"Macmillan Cancer Support"},{"id":"macmillan-support-line","kind":"collection","name":"Macmillan Support Line","aka":[],"tldr":"Macmillan's free line, 0808 808 00 00, puts you through to a nurse, a benefits adviser or a money adviser, seven days a week.","summary":"The Macmillan Support Line is the UK's main charity helpline for anyone affected by cancer. Nurses answer clinical questions, welfare rights advisers help with benefits claims, financial guides help with money and energy costs, and work support advisers cover employment rights. Macmillan also gives one-off grants and runs information and support centres in many hospitals. Calls are free from UK landlines and mobiles.","asOf":"2026-09-17","links":[{"label":"Macmillan Support Line","url":"https://www.macmillan.org.uk/"}],"tags":["free","helpline"],"related":["src-macmillan","nci-cancer-information-service","cruk-nurse-helpline","acs-cancer-helpline","cancercare","cancer-support-community","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.macmillan.org.uk/","holds":"Free UK support line (0808 808 00 00, seven days a week) with cancer nurses, welfare rights and financial guidance advisers, and work support, plus an online community and local information centres.","maintainer":"Macmillan Cancer Support"},{"id":"maggies-centres","kind":"collection","name":"Maggie's","aka":[],"tldr":"Maggie's centres sit next to NHS cancer hospitals and anyone can walk in, free, for support, benefits advice or a cup of tea.","summary":"Maggie's runs centres in the grounds of NHS cancer hospitals throughout the UK, plus a few abroad. Each is staffed by cancer support specialists, benefits advisers and psychologists, and runs courses such as Where Now for people finishing treatment, exercise and nutrition sessions, and groups for families. No referral or appointment is needed and everything is free. It is the model for hospital-adjacent support that other countries have copied.","asOf":"2026-09-17","links":[{"label":"Maggie's","url":"https://www.maggies.org/"}],"tags":["free","patient-org"],"related":["penny-brohn-uk","livestrong-at-the-ymca","look-good-feel-better","imerman-angels","first-descents","kesem"],"cancers":[],"sections":[],"technologies":["psycho-oncology","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.maggies.org/","holds":"Free practical, emotional and social support for anyone with cancer and their families in purpose-built centres next to NHS cancer hospitals across the UK: cancer support specialists, benefits advice, psychological support, exercise and relaxation groups, without appointment or referral.","maintainer":"Maggie's"},{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","aka":[],"tldr":"Medscape Oncology publishes broad clinician news with continuing-education tie-ins.","summary":"Medscape Oncology publishes broad clinician news, perspectives and continuing medical education for oncologists, with continuing-education tie-ins to its news coverage. It is run by WebMD and Medscape, publishes daily, and is free with registration. Its breadth means it touches most oncology stories, while the perspectives pieces add clinician commentary. On OnCo it is listed as a source with the tags source and news, one of the clinician-facing daily feeds OnCo reads for broad coverage and expert perspective.","asOf":"2026-09-08","links":[{"label":"Medscape Oncology","url":"https://www.medscape.com/oncology"}],"tags":["source","news"],"related":["src-healio-hemonc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.medscape.com/oncology","holds":"News, perspectives, and CME for oncologists.","license":"Free with registration","maintainer":"WebMD / Medscape"},{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","aka":[],"tldr":"A melanoma research funder created in 2007 by the Milken family that backed early immunotherapy and targeted-therapy work and now focuses on rare melanoma subtypes and resistance.","summary":"Founded 2007 (Debra and Leon Black with Michael Milken); 100% of donations go to research thanks to founders covering overhead. Funded early research on PD-1, BRAF/MEK combinations, neoadjuvant immunotherapy and TIL therapy; runs the RARE patient registry for acral and mucosal melanoma, the Dermatology Fellowship programme, and patient education on adjuvant and neoadjuvant choices. Partners with industry via the Melanoma Research Alliance Team Science Awards.","asOf":"2026-09-08","links":[{"label":"MRA","url":"https://www.curemelanoma.org/"},{"label":"AIM at Melanoma","url":"https://www.aimatmelanoma.org/"}],"tags":["gap-fill","patient-org"],"related":["melanoma","uveal-melanoma","pd1","braf","til-therapy"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.curemelanoma.org/","holds":"The largest private funder of melanoma research (>$150 million), patient and caregiver resources, the RARE Registry for acral and mucosal melanoma, and the annual scientific retreat.","license":"Copyright MRA","maintainer":"MRA"},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","aka":[],"tldr":"The Multiple Myeloma Research Foundation, founded by a patient in 1998, built CoMMpass, the largest open longitudinal genomic dataset in myeloma with 1,143 patients followed for over eight years, and helped fund early trials of bortezomib, lenalidomide, daratumumab and CAR-T. It also runs patient navigation and an immunotherapy hub.","summary":"Founded 1998 by Kathy Giusti (a patient). CoMMpass (2011-) followed newly diagnosed patients with whole-genome, exome and RNA sequencing over 8+ years, producing dozens of papers and the basis of new risk models; data are shared with academia and industry. The MMRF helped fund early trials of bortezomib, lenalidomide, daratumumab and CAR-T, runs the Multiple Myeloma Research Consortium of academic centres, and provides patient navigators and an Immunotherapy Hub. Frequently cited as the template for patient-founded research organisations.","asOf":"2026-09-08","links":[{"label":"MMRF","url":"https://themmrf.org/"},{"label":"CoMMpass","url":"https://themmrf.org/finding-a-cure/our-work/the-mmrf-commpass-study/"}],"tags":["gap-fill","patient-org"],"related":["multiple-myeloma","bcma","gprc5d","cd38","wes-wgs","rna-seq"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["mmrf-myeloma-investment-fund"],"institutions":[],"pathways":[],"terms":["r-iss","high-risk-myeloma","mrd-negativity-myeloma"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://themmrf.org/","holds":"CoMMpass longitudinal genomic study (1,143 patients, open data), MMRF CureCloud, Myeloma Accelerator Challenge, patient navigation, and a venture arm; the model of a data-driven disease foundation.","license":"CoMMpass data via dbGaP / MMRF Researcher Gateway","maintainer":"MMRF"},{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","aka":[],"tldr":"The National Brain Tumor Society is the largest US brain tumour nonprofit. It co-founded GBM AGILE, the adaptive platform trial that has enrolled more than 1,500 glioblastoma patients across several drug arms at once, funds research collaboratives, and lobbies the FDA on endpoints for brain tumours.","summary":"Formed 2008 (merger of the Brain Tumor Society and the National Brain Tumor Foundation). NBTS funds research collaboratives, co-founded the Global Coalition for Adaptive Research (GBM AGILE, which has enrolled >1,500 patients across regorafenib, paxalisib, VAL-083 and other arms, reporting the first results 2023-24), convenes the Brain Tumor Investment Fund, and leads advocacy (e.g. Head to the Hill, DIPG/DMG legislation). Patient resources include a personalised support and navigation programme.","asOf":"2026-09-08","links":[{"label":"NBTS","url":"https://braintumor.org/"},{"label":"GBM AGILE","url":"https://www.gcaresearch.org/gbm-agile/"}],"tags":["gap-fill","patient-org"],"related":["glioblastoma","medulloblastoma","primary-cns-lymphoma","basket-umbrella-platform","dordaviprone","vorasidenib"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["h3k27m","mgmt"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://braintumor.org/","holds":"Patient and caregiver resources, the GBM AGILE adaptive platform trial (co-founder via GCAR), the Defeat GBM and Defeat Pediatric Brain Tumors research collaboratives, policy advocacy and the Brain Tumor Registry initiatives.","license":"Copyright NBTS","maintainer":"NBTS"},{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","aka":[],"tldr":"Nature Briefing: Cancer is one email a week that catches the papers you missed.","summary":"Nature Briefing: Cancer is a weekly email digest of cancer research and news curated by Nature editors, one email a week that catches the papers you missed. It is sent weekly by Nature Portfolio and is a free email newsletter. It is a lightweight way to keep up with the cancer papers across the Nature titles and beyond without scanning each journal, and it works as a safety net for anything the daily feeds missed. On OnCo it is tagged source and news, and the journal record Nature links to it.","asOf":"2026-09-08","links":[{"label":"Nature Briefing: Cancer","url":"https://www.nature.com/briefing/cancer"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"url":"https://www.nature.com/briefing/cancer","holds":"A weekly email digest of cancer research and news curated by Nature editors.","license":"Free email","maintainer":"Nature Portfolio"},{"id":"nature-index","kind":"collection","name":"Nature Index: Healthcare and Cancer institutions","aka":[],"tldr":"The Nature Index shows which institutions publish the most top-tier research. It is the best public proxy for university output in cancer science.","summary":"The Nature Index tracks research output in 145 high-quality journals by institution, with tables for healthcare and cancer-specific research, which makes it the best public proxy for university output in cancer science. Its fractional Share metric counts authorship contributions, and the 2025 research leaders tables are based on 2024 output; Harvard, the Chinese Academy of Sciences and West China Hospital lead the healthcare tables. It is published by Nature Portfolio and is public. OnCo uses it as a public proxy for the research output of the institutions it lists, showing which of them publish the most top-tier research.","asOf":"2026-09-04","links":[{"label":"Top 10 healthcare institutions","url":"https://www.nature.com/nature-index/news/worlds-top-ten-healthcare-institutions-scientific-research"}],"tags":[],"related":["scimago-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"url":"https://www.nature.com/nature-index/research-leaders/2025/institution/healthcare/all/global","holds":"Research output in 145 high-quality journals by institution, including healthcare and cancer-specific tables.","license":"Public","maintainer":"Nature Portfolio"},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","aka":[],"tldr":"The algorithms US oncologists follow. If a drug is in NCCN, insurers usually pay.","summary":"The NCCN Guidelines are US clinical practice guidelines for every cancer type, updated continuously by the National Comprehensive Cancer Network, an alliance of 33 US centres. They are the algorithms US oncologists follow, each option carries a category of evidence and a preference ranking, and patient versions are also published; if a drug appears in NCCN, US insurers usually pay for it. Access is free with registration for non-commercial use. On OnCo the guidelines are linked to the term Standard of care and the institution National Comprehensive Cancer Network (NCCN), and they are cited by the bottlenecks Prices and value, Fragmented care and guideline gaps, Knowledge reaches practice too slowly and Misinformation and unproven therapies, among others.","asOf":"2026-09-04","links":[{"label":"NCCN Guidelines","url":"https://www.nccn.org/guidelines"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nccn.org/guidelines","holds":"US clinical practice guidelines for every cancer type, updated continuously.","license":"Free with registration (non-commercial)","maintainer":"National Comprehensive Cancer Network (33 US centres)"},{"id":"nci-cancer-information-service","kind":"collection","name":"NCI Cancer Information Service","aka":[],"tldr":"Call 1-800-4-CANCER and a trained NCI specialist answers your questions about any cancer, free, in English or Spanish.","summary":"The Cancer Information Service is the National Cancer Institute's public help line. Information specialists answer questions about diagnosis, treatment, side effects, trials and NCI's own PDQ summaries, and can search for trials that match a caller's situation. It is free, confidential and open to anyone anywhere, though the trial search focuses on the US. OnCo's plain-language records draw on the same PDQ source the specialists use.","asOf":"2026-09-17","links":[{"label":"NCI Cancer Information Service","url":"https://www.cancer.gov/contact"}],"tags":["free","helpline"],"related":["cancer-gov-pdq","macmillan-support-line","cruk-nurse-helpline","acs-cancer-helpline","cancercare","cancer-support-community","krebsinformationsdienst","breast-cancer-now-helpline"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.gov/contact","holds":"Free, confidential answers about cancer from NCI information specialists by phone (1-800-4-CANCER), live chat and email, in English and Spanish, including help finding clinical trials.","maintainer":"US National Cancer Institute"},{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","aka":[],"tldr":"NCI CDAS holds the lung screening trial images that trained Sybil and most lung-nodule AI.","summary":"NCI CDAS holds the lung screening trial images that trained Sybil and most lung-nodule AI. The collection includes low-dose CT images and outcomes from the National Lung Screening Trial, which enrolled 53,000 smokers, together with PLCO screening data, available to approved researchers through a data access request. The NLST CT archive has become the standard resource for building lung cancer risk models. It is maintained by the NCI, is linked to the National Cancer Institute (NIH) and to the technology Sybil (MIT/MGH lung cancer risk from CT), and is referenced by the paper on the NLST result that yearly low-dose CT scans cut lung cancer deaths in heavy smokers.","asOf":"2026-09-08","links":[{"label":"NCI CDAS: NLST and PLCO screening trial data","url":"https://cdas.cancer.gov"}],"tags":["data"],"related":[],"cancers":[],"sections":[],"technologies":["sybil"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://cdas.cancer.gov","holds":"Low-dose CT images and outcomes from the National Lung Screening Trial, and PLCO screening data, available to approved researchers.","license":"Data access request","maintainer":"NCI"},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","aka":[],"tldr":"The Imaging Data Commons is TCIA in the cloud, ready for large-scale model training.","summary":"The NCI Imaging Data Commons (IDC) is TCIA moved into the cloud, ready for large-scale model training. It holds a cloud-hosted, DICOM-standardised copy of TCIA and other collections, queryable with BigQuery and viewable in the browser, and it supports pathology whole-slide images as DICOM. It forms part of the Cancer Research Data Commons alongside the Genomic Data Commons, is maintained by the NCI Cancer Research Data Commons, and is linked to the National Cancer Institute (NIH). Access terms are set per collection. The resource is referenced by the roadmaps on AI in the oncology clinic and on AI in oncology from pattern readers to foundation models to agents in the workflow.","asOf":"2026-09-08","links":[{"label":"NCI Imaging Data Commons (IDC)","url":"https://portal.imaging.datacommons.cancer.gov"}],"tags":["data"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://portal.imaging.datacommons.cancer.gov","holds":"Cloud-hosted, DICOM-standardised copy of TCIA and other collections, queryable with BigQuery and viewable in the browser.","license":"Per collection","maintainer":"NCI Cancer Research Data Commons"},{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","aka":[],"tldr":"The NCI's PDQ summaries are the most reliable free, plain-language explanation of each cancer's treatment.","summary":"The NCI PDQ Cancer Information Summaries are peer-reviewed, regularly updated summaries of treatment, screening and genetics for every cancer, each in a health-professional version and a plain-language patient version. They are the most reliable free explanation of each cancer's treatment, written and maintained by NCI editorial boards, published in English and Spanish, released as public domain, and used as the basis for many patient-facing sites. On OnCo they are cited by the bottlenecks Knowledge reaches practice too slowly, Patients lack understanding, navigation and agency and Misinformation and unproven therapies, by the idea A plain-language explainer for every guideline recommendation, in every major language, and by the collection American Cancer Society (ACS).","asOf":"2026-09-04","links":[{"label":"NCI PDQ Cancer Information Summaries","url":"https://www.cancer.gov/publications/pdq"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.gov/publications/pdq","holds":"Peer-reviewed, regularly updated summaries on treatment, screening, and genetics for every cancer, in health-professional and patient versions.","license":"Public domain","maintainer":"NCI"},{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","aka":[],"tldr":"NCI-designated cancer centres are the US government's list of the cancer centres that meet its research and care standards.","summary":"The NCI-Designated Cancer Centers list is the US government's roster of the cancer centres that meet the National Cancer Institute's standards for research and care: 74 centres in 2026, of which 58 are Comprehensive, 8 Clinical and 8 Basic Laboratory. Designation depends on a competitive P30 grant that must be renewed every five years. The list is maintained by the NCI and is public. On OnCo it is linked to the institution records of designated centres, from the O'Neal Comprehensive Cancer Center at UAB to The Jackson Laboratory Cancer Center, and it is cited by the bottlenecks Not enough oncologists, nurses, pathologists, physicists and Fragmented care and guideline gaps and by the idea Promote academics for trials completed, data shared and findings replicated.","asOf":"2026-09-04","links":[{"label":"NCI-Designated Cancer Centers","url":"https://www.cancer.gov/research/infrastructure/cancer-centers"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci","oneal-uab","arizona-cancer-center","uc-davis-cancer","iowa-holden","ku-cancer-center","maryland-greenebaum","karmanos","minnesota-masonic","dartmouth-cancer-center","rutgers-cinj","unm-cancer-center","montefiore-einstein","wake-forest-cancer","fox-chase","vcu-massey","uva-cancer-center","uw-carbone","uf-health-cancer-center","nebraska-buffett","musc-hollings","mays-cancer-center","salk-institute","sanford-burnham-prebys","cancer-center-at-illinois","purdue-cancer-research","jackson-laboratory","wistar","mayo-clinic-florida","mayo-clinic-arizona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancer.gov/research/infrastructure/cancer-centers","holds":"The 74 US centres holding NCI designation (58 Comprehensive, 8 Clinical, 8 Basic Laboratory).","license":"Public","maintainer":"NCI"},{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","aka":[],"tldr":"The Newsweek/Statista ranking is the most-cited global hospital ranking for cancer care. OnCo uses it as one input to its institution table.","summary":"The Newsweek/Statista World's Best Specialized Hospitals ranking for oncology is an annual list of 300 oncology hospitals scored by peer survey, patient experience and quality metrics, and it is the most-cited global hospital ranking for cancer care. Most of the score comes from a survey of more than 85,000 medical professionals, with the remainder from patient surveys, accreditation and patient-reported outcome measures; the methodology PDF is linked. It is published by Newsweek and Statista and is public. OnCo uses it as one input to its institution table, and the institution records for Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Samsung Medical Center cite it.","asOf":"2026-09-04","links":[{"label":"Methodology 2026","url":"https://assets.newsweek.com/wp-content/uploads/2025/08/20250730_World%C2%B4s-Best-Specialized-Hospitals_2026_Methodology.pdf"}],"tags":[],"related":["nature-index","scimago-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://rankings.newsweek.com/worlds-best-specialized-hospitals-2026/oncology","holds":"Annual ranking of 300 oncology hospitals by peer survey, patient experience, and quality metrics.","license":"Public","maintainer":"Newsweek / Statista"},{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","aka":[],"tldr":"In the UK the NHS invites you to bowel, breast and cervical screening by age, free, and is rolling out lung screening for people who smoke or used to.","summary":"The NHS runs population screening for bowel cancer (a faecal immunochemical test posted to the home every two years), breast cancer (mammography every three years) and cervical cancer (HPV primary testing), with age ranges that differ slightly between England, Scotland, Wales and Northern Ireland; the NHS page for each programme states the current ages. Lung cancer screening with low-dose CT for people aged 55 to 74 who smoke or used to, begun as the Targeted Lung Health Check, is being extended across England. Screening is free, invitations are automatic through the GP register, and anyone who has missed an invitation can ask their GP practice. Screening looks for cancer or pre-cancer in people without symptoms; anyone with symptoms should see a GP rather than wait for screening.","asOf":"2026-09-17","links":[{"label":"NHS cancer screening programmes","url":"https://www.nhs.uk/conditions/nhs-screening/"},{"label":"NHS bowel cancer screening","url":"https://www.nhs.uk/conditions/bowel-cancer-screening/"},{"label":"NHS breast screening","url":"https://www.nhs.uk/conditions/breast-screening-mammogram/"},{"label":"NHS cervical screening","url":"https://www.nhs.uk/conditions/cervical-screening/"}],"tags":["free","public"],"related":["australia-cancer-screening-programs","ireland-national-screening-service","nz-time-to-screen","cdc-nbccedp"],"cancers":["colorectal","breast-cancer","cervical","nsclc"],"sections":[],"technologies":["colorectal-screening","mammography","nhs-targeted-lung-health-check","low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nhs.uk/conditions/nhs-screening/","holds":"The three national NHS cancer screening programmes, free at the point of use and invitation-based: bowel screening by home FIT kit, breast screening by mammogram, and cervical screening with HPV testing; plus lung screening for people with a smoking history, being rolled out across England.","maintainer":"NHS England (and the devolved NHS bodies)"},{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","aka":[],"tldr":"In England, tumour and inherited cancer gene testing is free on the NHS when the National Genomic Test Directory lists it for your cancer. Your hospital team orders it.","summary":"The NHS Genomic Medicine Service brings cancer genomic testing under one national structure. The National Genomic Test Directory, updated each year, states which tests the NHS funds for which indication, from single-gene companion tests to large panels, whole genome sequencing for some cancers, and germline testing where family history or tumour features meet the criteria. Regional Genomic Laboratory Hubs run the tests; clinical teams order them and there is no charge to the patient. Scotland, Wales and Northern Ireland run their own genomic services with similar principles. For a patient, the practical questions are whether the directory lists a test for their situation and whether the team has requested it.","asOf":"2026-09-17","links":[{"label":"NHS Genomic Medicine Service","url":"https://www.england.nhs.uk/genomics/nhs-genomic-med-service/"},{"label":"National Genomic Test Directory","url":"https://www.england.nhs.uk/publication/national-genomic-test-directories/"}],"tags":["free","patient-programme","public"],"related":["pancan-know-your-tumor","prostate-cancer-promise","nhs-jewish-brca-testing"],"cancers":[],"sections":[],"technologies":["cgp","wes-wgs","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.england.nhs.uk/genomics/nhs-genomic-med-service/","holds":"The NHS route to tumour and inherited-risk testing in England, free at the point of use for eligible patients: the National Genomic Test Directory lists which tests are funded for which cancers, delivered through regional Genomic Laboratory Hubs.","maintainer":"NHS England"},{"id":"nhs-healthcare-travel-costs-scheme","kind":"collection","name":"NHS Healthcare Travel Costs Scheme","aka":[],"tldr":"If you are on certain benefits or a low income in England, the NHS refunds your travel costs to hospital appointments, including cancer treatment.","summary":"The Healthcare Travel Costs Scheme repays fares or mileage for NHS-referred hospital appointments to people who receive qualifying benefits or hold an HC2 or HC3 certificate under the NHS Low Income Scheme. Claims are made at the hospital cashier or by post within three months, and the cost of a travelling companion is covered when medically necessary. It is small but it removes one of the commonest reasons for missed appointments. Macmillan advisers can help with the claim.","asOf":"2026-09-17","links":[{"label":"NHS Healthcare Travel Costs Scheme","url":"https://www.nhs.uk/nhs-services/help-with-health-costs/healthcare-travel-costs-scheme-htcs/"}],"tags":["free","public"],"related":["macmillan-support-line","acs-road-to-recovery","acs-hope-lodge","corporate-angel-network","ronald-mcdonald-house-charities","young-lives-vs-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nhs.uk/nhs-services/help-with-health-costs/healthcare-travel-costs-scheme-htcs/","holds":"Refund of the cost of travel to NHS hospital appointments for patients on qualifying benefits or with a low income (HC2 or HC3 certificate), claimed at the hospital or by post within three months.","maintainer":"NHS England"},{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","aka":[],"tldr":"The NHS gives the HPV vaccine free at school around age 12 to 13, and anyone who missed it can still get it free until they turn 25.","summary":"The NHS HPV programme began for girls in 2008 and was extended to boys in 2019; since 2023 a single dose is given in Year 8 in England. Anyone eligible who missed the school dose can have it free from their GP until their 25th birthday, and men who have sex with men aged up to 45 can have it at sexual health clinics. The programme has already cut cervical cancer sharply in the first vaccinated cohorts, which is why OnCo lists it among the highest-value free things in oncology.","asOf":"2026-09-17","links":[{"label":"NHS HPV vaccination programme","url":"https://www.nhs.uk/vaccinations/hpv-vaccine/"}],"tags":["free","public"],"related":["paper-hpv-vaccine-england-lancet-2021","us-vaccines-for-children","gavi-hpv-programme"],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nhs.uk/vaccinations/hpv-vaccine/","holds":"Free HPV vaccination offered in school (Year 8 in England), with free catch-up for anyone who missed it until their 25th birthday and for men who have sex with men up to 45 through sexual health clinics.","maintainer":"NHS England"},{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","aka":[],"tldr":"Anyone in England with a Jewish grandparent can order a free NHS saliva test for BRCA gene changes, which raise breast, ovarian, prostate and pancreatic cancer risk.","summary":"People of Jewish ancestry carry BRCA1 or BRCA2 founder variants far more often than the general population, and most carriers have no family history that would qualify them for testing. The NHS Jewish BRCA Testing Programme removes the family-history gate: adults in England with one or more Jewish grandparent register online, receive a saliva kit at home, and get their result with genetic counselling if a variant is found. The programme is run by NHS England with the charities Jnetics and Chai Cancer Care, and the website sets out who is eligible and what a positive result leads to (surveillance, risk-reducing options, cascade testing of relatives).","asOf":"2026-09-17","links":[{"label":"NHS Jewish BRCA Testing Programme","url":"https://www.jewishbrca.org/"}],"tags":["free","patient-programme","public"],"related":["hereditary-cancer-syndromes","pancan-know-your-tumor","prostate-cancer-promise","nhs-genomic-medicine-service"],"cancers":["breast-cancer","ovarian","prostate","pancreatic"],"sections":[],"technologies":["germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.jewishbrca.org/","holds":"Free BRCA1 and BRCA2 testing by saliva kit for anyone in England aged 18 or over with at least one Jewish grandparent, regardless of family history, with genetic counselling for those who test positive.","maintainer":"NHS England with Jnetics and Chai Cancer Care"},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","aka":[],"tldr":"NICE decides which cancer treatments the NHS pays for, publishing for each drug an appraisal of cost per quality-adjusted life year against a threshold of £25,000 to £35,000, plus clinical guidelines. Because the manufacturer models and committee reasoning are public, its decisions serve as an independent view of a drug's value that often diverges from FDA and EMA licensing.","summary":"NICE technology appraisals (since 1999) assess clinical and cost-effectiveness against a threshold of £25,000-35,000 per QALY since 2 April 2026, raised from £20,000-30,000 (with severity modifiers, which replaced the end-of-life rule in 2022), and can recommend, restrict, or route drugs to the Cancer Drugs Fund for data collection. Clinical guidelines (e.g. NG12 suspected cancer recognition and referral) set diagnostic pathways. Appraisal documents contain manufacturer models, evidence review group critiques and committee reasoning, making them one of the most transparent public sources on drug value; decisions often diverge from FDA/EMA licensing.","asOf":"2026-09-08","links":[{"label":"NICE cancer topic page","url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer"}],"tags":["gap-fill","guidelines"],"related":["nccn","esmo-guidelines"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["drug-price-transparency","hazard-ratio","os","pfs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer","holds":"UK clinical guidelines (NG series), technology appraisals with cost-effectiveness decisions for every new cancer drug (including Cancer Drugs Fund managed access), quality standards and pathways.","license":"Open Government Licence / NICE terms","maintainer":"National Institute for Health and Care Excellence"},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","aka":[],"tldr":"NICE technology appraisals say whether the NHS will pay, and why. They are the most transparent HTA record in the world.","summary":"NICE technology appraisals record England's cost-effectiveness decisions for cancer drugs, with committee papers and prices where disclosed, so they say whether the NHS will pay and why. Published continuously by the National Institute for Health and Care Excellence, the TA documents include the evidence review and often the only public sight of the confidential discounts being negotiated, which makes them the most transparent HTA record in the world. The documents are public. On OnCo the source is tagged source and data, and it is linked from the institution record National Institute for Health and Care Excellence and from the Global access and affordability roadmap.","asOf":"2026-09-08","links":[{"label":"NICE technology appraisals","url":"https://www.nice.org.uk/guidance/published?type=ta"}],"tags":["source","data"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nice.org.uk/guidance/published?type=ta","holds":"England's cost-effectiveness decisions for cancer drugs, with committee papers and prices where disclosed.","license":"Public","maintainer":"National Institute for Health and Care Excellence"},{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","aka":[],"tldr":"npj Precision Oncology is a Nature Portfolio journal that publishes genomics, artificial intelligence and biomarker studies continuously rather than in issues. Every article is open access under a CC BY licence, so it can be read in full without a subscription.","summary":"npj Precision Oncology is a Nature Portfolio journal that publishes continuously rather than in issues, holding open-access precision oncology research: genomics, AI and biomarker studies. It is the open-access home for genomics and AI-in-oncology papers, so its articles can be read in full without a subscription. Articles are open access under CC BY. On OnCo it is listed as a source with the tags source and journal, alongside the other journals OnCo reads for precision oncology.","asOf":"2026-09-08","links":[{"label":"npj Precision Oncology","url":"https://www.nature.com/npjprecisiononcology/"}],"tags":["source","journal"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.nature.com/npjprecisiononcology/","holds":"Open-access precision oncology: genomics, AI, biomarker studies.","license":"Open access (CC BY)","maintainer":"Nature Portfolio"},{"id":"src-onclive","kind":"collection","name":"OncLive","aka":[],"tldr":"OncLive, run by MJH Life Sciences, publishes daily oncology news, approval alerts and video interviews with trial investigators, often within hours of a readout. Industry-sponsored content is common, so check numbers against the primary source before relying on them.","summary":"OncLive publishes daily oncology news, approval alerts and expert video interviews, delivering fast approval and readout news together with interviews with trial investigators and specialists. It is run by MJH Life Sciences and is free, with registration required for some content. Industry-sponsored content is common, so numbers should be checked against the primary source before they are relied on. On OnCo it is tagged source and news, and the sibling collection Targeted Oncology links to it.","asOf":"2026-09-08","links":[{"label":"OncLive","url":"https://www.onclive.com/"}],"tags":["source","news"],"related":["src-cancer-network","src-targeted-oncology","src-cancer-letter","src-oncodaily","src-healio-hemonc","src-medscape-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.onclive.com/","holds":"Daily oncology news, approval alerts, and expert video interviews.","license":"Free with registration for some content","maintainer":"MJH Life Sciences"},{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","aka":[],"tldr":"OncoDaily publishes a high volume of daily oncology news, education and career items from outside the United States, which is the perspective US-centred feeds lack. It is free, but trial news is mixed with profiles and history pieces, so check primary sources before reusing a figure.","summary":"OncoDaily publishes high-volume daily oncology news with international reach, holding global oncology news, education and career items with a strong non-US voice. It is free to read and maintained by OncoDaily. Trial news is mixed with profiles and history pieces, so primary sources should be checked before a figure is reused. Its value on OnCo is the international perspective that US-centred feeds lack. On OnCo it is listed as a source with the tags source and news.","asOf":"2026-09-08","links":[{"label":"OncoDaily","url":"https://oncodaily.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://oncodaily.com/","holds":"Global oncology news, education, and career items, with a strong non-US voice.","license":"Free","maintainer":"OncoDaily"},{"id":"oncokb","kind":"collection","name":"OncoKB","aka":[],"tldr":"Tells you, for a given mutation, whether an approved or investigational drug exists and how strong the evidence is.","summary":"OncoKB holds curated levels of evidence for the clinical actionability of somatic alterations, so that for a given mutation a reader can see whether an approved or investigational drug exists and how strong the evidence is. Memorial Sloan Kettering maintains it; it is free for academic use with a commercial licence, and was recognised by the FDA as a human variant database in 2021. Levels 1 to 4 grade therapeutic evidence and R1 and R2 mark resistance; an API is available and it is used by cBioPortal and many molecular tumour boards. On OnCo it sits under the technology Comprehensive genomic profiling and the related record Cancer variant knowledgebases and molecular tumour boards, and it is cited by the bottleneck Knowledge reaches practice too slowly and by several ideas.","asOf":"2026-09-04","links":[{"label":"OncoKB","url":"https://www.oncokb.org"}],"tags":[],"related":["variant-knowledgebases"],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.oncokb.org","holds":"Curated levels of evidence for the clinical actionability of somatic alterations.","license":"Free for academic use; commercial licence","maintainer":"Memorial Sloan Kettering"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","aka":[],"tldr":"Open Targets scores how strongly each gene is linked to each disease, with the evidence behind it.","summary":"The Open Targets Platform scores how strongly each gene is linked to each disease and exposes the evidence behind the score, integrating genetics, expression, literature and drug data into target-disease associations. It also carries ChEMBL drug data, safety liabilities, tractability assessments and the Open Targets Genetics results. The platform is a partnership of EMBL-EBI, the Wellcome Sanger Institute, GSK, Sanofi, BMS, Pfizer and Genentech, released as open data under CC0. On OnCo it is filed under AI-driven drug and target discovery and is cited by the bottlenecks The undruggable drivers, No incentive to repurpose cheap drugs and The valley of death between lab and product, and by ideas such as A target de-risking index that counts failures as well as successes.","asOf":"2026-09-04","links":[{"label":"Open Targets Platform","url":"https://platform.opentargets.org"}],"tags":[],"related":["ttd"],"cancers":[],"sections":[],"technologies":["ai-drug-design"],"targets":["ctnnb1","ccnd1","tert","pole","apc","fgfr4","pold1","nrg1","tsc1","mycn","setd2","tsc2","calr","eml4","esr2","pml","kif5b","lck","smad2","jak3","yes1","ccdc6","sem1","rbx1","fyn","prim1","tyk2","cd74","ephb2","syk","dpyd","sdc4","tubb3","pola2","prim2","psma4","pde3a","pold3","tuba1c","epha3","epha7","hdac4","top2b","blk","fgf7","prkcb","psmd7","prkd1","hdac9","itk","psmb7","prkci","tymp","hdac11","psmd6","irak1","psma6","epha4","thrb","psmd4","prkce","epha5","arnt","adrm1","tubb4b","ephb1","tuba3c","psmc1","psmd11","pdcd1lg2","rrm2","psmb8","rrm2b","tubb2b","prkcz","psma2","rarg","tubb4a","epha6","hdac7","psmd12","pole2","psma5","psmd14","tuba1b","psma7","cul4a","tubb6","parp2","psmc2","psma3","psmb9","fgf23","tubb2a","psmb10","prkch","psmd2","psmd1","ddb1","tuba1a","psmd3","pold4","tuba4a","fdps","psmb4","psmc5","psmd8","psma1","rarb","psmb2","pold2","psmd13","cd3d","pde3b","psmb6","psmc4","parp3","ptgs1","tubb1","psmb3","psmb1","psma8","ephb4","il2rg","psmc6","psmc3","psmb11","il2rb","scn3a","tgfb1","fgr","srd5a3","mapk11","ifnar2","tuba3e","srd5a1","cd3g","pole3","tubb8","hdac5","hdac8","hdac10","prkcq","casr","epha1","ephb3","epha10","ghsr","srms","kcnq1","prkd3","prkcg","impdh1","thra","prkcd","atp4b","epha8","sstr5","adra1a","atp4a","sstr1","ppat","kcnb2","kcnq5","cacna1h","adra2c","tgfb2","scn2a","scn8a","sstr4","slc6a3","sstr3","kcnh8","csf2rb","scn4a","kcnq3","scn5a","adra1b","cacna1g","ednra","scn9a","kcna3","scn7a","scn10a","scn1a","kcnd3","cacna1i","adra1d","kcnh1","pik3cg","cda","slc6a2","scn11a","slc6a4","kcnd2","ifna2","adra2a","cyp11b1","kcnh7","adra2b","kcna4","snap25","kcnf1","kcnc2","tgfb3","aph1a","aph1b","csnk1e","ncstn","psen2","psenen","tph2","vhl","pten","atm","cdkn2a","h3-3a","notch1","smad4","mlh1","dicer1","rb1","hras","smarcb1","smarca4","stk11","bap1","arid1a","ercc2","kmt2d","runx1","palb2","wt1","cebpa","fbxw7","msh2","chek2","msh6","cdh1","bcor","atrx","gnas","sf3b1","asxl1","etv6","cbl","pik3r1","kmt2c","kdm6a","pbrm1","pms2","crebbp","nfe2l2","ep300","cdk12","ccne1","bard1","brip1","rad51c","ddx41","lrp1b","rad51d","mapk1","flcn","nbn","srsf2","spop","u2af1","myc-gene","setbp1","gata2","map3k1","casp8","gnaq","sdha","fbxo11","cdkn1b","pik3cb","nf2","fat1","ppp2r1a","smad3","ccnd2","keap1","stag2","sh2b3","rad50","axin2","prkar1a","notch2","rad51b","rac1","gna11","foxa1","sos1","pot1","gata1","mitf","fancc","mecom","fanca","h3c2","plcg1","arhgap35","arid2","map2k4","stat3","lztr1","ercc4","ctcf","myod1","rhoa","arid1b","gata3","nt5c2","drosha","pparg","hgf","bcl11a","rasa1","hoxb13","fh","b2m","kdm5c","cic","mdm4","cdkn1a","mbd4","fhit","foxp1","rras2","araf","etv1","rpl5","pax5","spen","grin2a","ptprb","jun","ebf1","myb","pim1","ercc5","prex2","pdgfb","cdkn2b","hsp90aa1","mn1","cacna1d","ptprt","pik3r2","nr4a3","fubp1","foxo1","sdhb","il7r","erg","ercc3","fgf2","msh3","sufu","pax8","h3-3b","prdm1","ubr5","klf5","slc34a2","ddx3x","fgf1","klf4","card11","tet1","cblb","ccnd3","ikbkb","fgf4","tbl1xr1","bcl10","rictor","abl2","mre11","fgf3","etv5","grb2","etv4","itgb3","yap1","fgg","tfeb","prkn","crlf2","fcgr2b","klk3","fn1","atp1a1","cdx2","ereg","gsk3b","fga","myd88","birc6","btg1","fgb","mycl","egf","nsd2","tcf3","ciita","birc3","bcl6","rpl10","nfkbie","atg7","rpl22","pou5f1","rspo3","zrsr2","tgfbr1","rps27a","tnfrsf10b","mapk3","pcbp1","fas","tnfaip3","pik3r3","fto","actb","rel","ercc6","tnfrsf14","ppp2ca","p2ry8","hbegf","rabl3","icos","bach2","dcc","pou2af1","stat6","dll4","eif1ax","pdpk1","stat1","ndufa13","irs2","mapk8","aldh2","mapk9","mmp7","znf217","areg","ppp2cb","rad54l","fancl","cul3","nox4","psca","flt3lg","rfx7","chrna4","abcc1","klf2","hla-b","xrcc1","rps24","zfp36l1","rps29","mmp2","rps26","mt-nd6","vdr","tgfa","angpt1","pik3r5","hmgcr","rps19","socs1","cd200","mt-nd1","rps27","gabrg3","rps7","sgk1","mef2b","tmsb4x","id3","pou2f2","irf8","tgfbr2","axin1","cdc73","rnf43","amer1","tcf7l2","cux1","hnf1a","zfhx3","ppm1d","tbx3","tp63","maml2","suz12","recql4","trim24","ranbp2","klf6","acvr1b","bmpr1a","ncor1","acvr2a","cltc","rbm10","nkx2-1","qki","fat4","snd1","chd4","trrap","tmprss2","myh9","cbfb","max","usp6","hip1","nsd1","cdh11","daxx","cyld","tfg","rspo2","bcl11b","lats1","six1","bcl9l","rad21","prdm16","ncor2","maf","ptprk","tent5c","zbtb16","phf6","msi2","tpr","med12","bcorl1","ppp6c","ncoa2","zmym2","runx1t1","znf521","plag1","lats2","psip1","sall4","rap1b","ackr3","sox9","akap9","rap1gds1","kat6b","polq","ctnna1","csmd3","il6st","cdkn2c","cntrl","cnot3","trip11","aff4","ptpn13","crtc1","ptprc","col1a1","kat6a","afdn","clip1","nutm1","knl1","irf1","bcl9","elf4","usp8","nbea","arhgef12","ddb2","camta1","aff3","ell","foxo3","atp2b3","wwtr1","flg","ddx6","cltcl1","nsd3","nfatc2","eif3e","lef1","irs4","hnrnpa2b1","fus","nfkb2","nup98","pcm1","fcrl4","lrig3","trim33","rest","znf331","eps15","elk4","kdm5a","ing1","zmym3","tcl1a","rhpn2","malt1","elf3","tal2","traf7","was","nup214","hoxc13","pabpc1","tal1","lifr","msn","brd7","acsl3","mllt1","atf7ip","asxl2","znrf3","ptpn14","rps6ka3","lpa","h4c9","adamts9","znf750","rnf6","ncoa1","rbfox1","fmn2","myeov","znf429","gpc5","baz1a","mllt3","aff1","chd2","mutyh","ext1","fancd2","pax6","blm","xpa","sdhaf2","pax3","lpp","strn","bub1b","hnf1b","c11orf65","arhgap26","fgf10","rmi2","tfe3","fance","fancg","sdhc","elac2","mprip","mllt10","nthl1","tmem127","fancf","rad51","pax7","tpm3","ext2","sdhd","cars1","atic","cep43","gab2","mrtfa","srgap1","atf1","cbfa2t3","trim28","hmga2","xpc","xrcc2","sox2","fes","dnm2","ssx1","mlh3","ksr2","nrg3","exo1","jag1","prf1","maml3","ppp2r1b","fgf9","nfib","lmo1","stn1","iqgap1","vwf","rbbp8","kdm7a","hoxd11","ogg1","shc1","lmo2","pou5f1b","lrrfip1","lmna","ctr9","btc","frs2","hmga1","ddit3","sbds","hlf","gab1","sptbn1","wwox","kat2b","ss18","foxe1","oca2","erbin","tln1","mark3","mxi1","crtc3","etnk1","sfrp4","erlin2","myo18a","fgf5","csk","wif1","minpp1","msmb","fmn1","creb3l2","cdc37","creb1","fgf8","ndrg1","hoxa13","dll1","fgf18","ddx10","kitlg","creb3l1","kat2a","ksr1","apobec3b","ywhae","papss1","per1","map3k13","fancm","fgf20","ncoa4","tpm4","pbx1","arrb1","itga2b","fanci","abi1","ywhab","fgf17","dek","fgf16","kiaa1549","dctn1","mafb","maml1","vcl","sqstm1","phox2b","apbb1ip","fam131b","ssx2","rap1a","actg1","arrb2","ddx5","cnksr2","lyl1","aspscr1","bcl3","mamld1","patz1","trim27","smarce1","rmi1","trak1","nutm2b","rbpj","olig2","cnksr1","slc45a2","mlf1","fgf6","cpvl","hoxd13","hoxa11","cd79a","slc67a1","srsf3","tlx3","bag4","kank1","jazf1","hey1","nrg2","cyp1b1","rhoh","mtcp1","cpsf6","tlx1","smad7","hoxc11","golgb1","nrg4","habp2","sh3gl1","fgf22","fgfr1op2","cnbp","mc1r","prkaca","slx4","ezr","otx1","ppp2r5a","ktn1","snw1","znf462","prc1","ppp2r5c","adh1b","krt5","jag2","tyr","csnk1a1","spdl1","rtel1","ap3b1","ppp1r14a","erc1","fev","ccnb1ip1","ano7","rnasel","msr1","esrp1","zmiz1","gopc","trps1","tg","dnmt3b","tnfrsf13b","polk","neil1","tox3","aggf1","usp28","dock8","stil","tns3","ppfibp1","dnajb1","agtrap","foxo4","ppp2r5e","sfpq","fxr1","bnc2","ctsh","eed","agk","lmo7","ctss","casp10","tent4a","poglut3","cdca7","tgm3","grem1","inhbb","lamc1","rnaset2","golga5","ppp2r5d","wdcp","rassf6","zc3hav1","pnpla3","nab2","chchd7","rhobtb2","tyrp1","dna2","bmp4","sdccag8","naf1","kat5","dclre1b","clcn6","vps53","top3a","fip1l1","irs1","ppp2r5b","sntb1","fam114a2","tcea1","slc22a3","apoe","slc24a5","hook3","zbtb10","abo","ccdc170","hhip","lig4","chrna5","eif2ak3","golga4","fermt2","pms1","prcc","tmem17","tpcn2","ehbp1","fancb","dlc1","lrp5","plxnb2","ubc","nr5a2","tmem238l","arhgef5","ubb","l3mbtl3","itga6","ptpn22","lama5","lsp1","bmp5","sim2","ccnh","irf5","klc1","skp1","uba52","cul1","chmp4c","mov10","igf2r","rgs17","clptm1l","zfpm2","incenp","lrfn2","ppm1b","tnfsf10","pax9","rcc2","nrip1","tns1","irx4","mx2","adam29","mt-cyb","tbx1","ccdc88c","rbbp7","foxp4","itpr1","skil","nek10","celf2","toe1","bik","sidt1","grhl2","frs3","gdf7","vti1a","bmp2","dnah11","chrna3","herpud1","dnajc1","pcnx2","wrap53","samd9l","slc14a1","zfhx4","mlph","rfwd3","cdkal1","ebf2","hnf4g","elp4","sorcs3","mcm8","tbpl1","pdgfrl","pdlim5","lmx1b","mt-co1","nkx3-1","a1cf","lratd2","eomes","bak1","set","arid5b","acoxl","acta2","dlst","elp1","gnb1","gpr161","klhdc8b","mysm1","pald1","samd9","slc25a11"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://platform.opentargets.org","holds":"Target-disease association evidence integrating genetics, expression, literature, and drugs.","license":"CC0 / open","maintainer":"EMBL-EBI, Sanger, GSK, Sanofi, BMS, Pfizer, Genentech"},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","aka":[],"tldr":"The Ovarian Cancer Research Alliance is the largest US ovarian cancer organisation, born from the merger of research and patient-support charities; it funds research and campaigns for universal genetic testing and prevention by salpingectomy given that screening does not work.","summary":"Formed 2016 (Ovarian Cancer Research Fund + Ovarian Cancer National Alliance), absorbing the National Ovarian Cancer Coalition in 2023. Funds >$100 million in research, runs the Woman to Woman peer programme in 50+ hospitals, advocates for germline testing of all patients and cascade testing, and in 2023 endorsed opportunistic salpingectomy for prevention after the UKCTOCS trial confirmed screening does not reduce mortality. Also produces patient education on PARP inhibitors and maintenance therapy.","asOf":"2026-09-08","links":[{"label":"OCRA","url":"https://ocrahope.org/"}],"tags":["gap-fill","patient-org"],"related":["ovarian","brca","parp-inhibitor","risk-reducing-salpingectomy","hrd","ca-125"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hgsoc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://ocrahope.org/","holds":"Patient support (Woman to Woman mentoring, Staying Connected), research grants, advocacy on genetic testing and the Ovarian Cancer Research Fund/NOCC-merged programmes, and policy work on the failure of screening.","license":"Copyright OCRA","maintainer":"OCRA"},{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","aka":[],"tldr":"PanCAN pays for tumour sequencing for people with pancreatic cancer in the US, so the results can point to a targeted drug or a trial.","summary":"Know Your Tumor is the Pancreatic Cancer Action Network's precision medicine service. Patients or their oncologists apply through PanCAN Patient Services; the charity coordinates collection of tumour tissue and pays for comprehensive genomic profiling, then returns a report to the treating oncologist. PanCAN's published analyses of the programme found that a minority of patients carry an actionable alteration and that those treated on a matched therapy lived longer, which is the argument for testing everyone. The programme is limited to the United States and the programme page states the current eligibility rules.","asOf":"2026-09-17","links":[{"label":"PanCAN Know Your Tumor","url":"https://pancan.org/facing-pancreatic-cancer/patient-services/know-your-tumor/"}],"tags":["free","patient-programme"],"related":["pancan","prostate-cancer-promise","nhs-genomic-medicine-service","nhs-jewish-brca-testing"],"cancers":["pancreatic"],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://pancan.org/facing-pancreatic-cancer/patient-services/know-your-tumor/","holds":"A free molecular profiling service for people with pancreatic cancer in the United States: tumour sequencing arranged through the patient's oncologist, with a report the treating team can use to look for targeted treatments and trials.","maintainer":"Pancreatic Cancer Action Network"},{"id":"pancaresurfup","kind":"collection","name":"PanCareSurFup and the European survivor cohorts","aka":["PanCareSurFup","PanCare","PanCareLIFE","PanCareFollowUp"],"tldr":"Europe's answer to the American cohorts: thirteen data providers in twelve countries pooled their records to build what its own authors call the largest cohort of children with cancer to date, 83,333 five-year survivors, so that second cancers and heart disease could be counted on a continent that keeps its data in national pieces.","summary":"PanCare is a European network of professionals, survivors and families working on the late effects of childhood and adolescent cancer. PanCareSurFup, the PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies consortium, was its data-pooling project. Thirteen data providers from twelve countries delivered records to a central data centre in Mainz using a single variable list, with validity and plausibility checks before analysis. In total the project collected data on 115,596 patients diagnosed with cancer between 1940 and 2011, of whom 83,333 had survived five years or more.\n\nThe outcome-specific cohorts differ in size because eligibility differs. From a cohort of 39,152 five-year survivors, 1,014 patients with at least one cardiac event were identified. For second cancers, 3,995 survivors developed at least one second cancer out of a cohort of 71,494. From the late-mortality cohort of 79,441, 9,247 died subsequently. The authors describe the achievement in their own words: \"Through the close cooperation of many European countries and the establishment of one central data collection and harmonising centre, the project succeeded in generating the largest cohort of children with cancer to date.\"\n\nThe network's other projects answer different questions. PanCareLIFE worked on fertility, ototoxicity and quality of life, and with the International Guideline Harmonization Group produced the 2021 fertility preservation guidelines for female and male patients diagnosed at 25 or younger. PanCareFollowUp built and tested a person-centred survivorship care intervention in European clinics, with a training package for the staff who deliver it, evaluated across four survivorship clinics. The network also developed the Survivorship Passport, a structured treatment summary a survivor carries with them, which exists because the commonest practical obstacle to risk-based follow-up is that nobody can find out what the person was given.\n\nThe gap Europe still has is the denominator. A 2024 scoping review of prevalence of childhood cancer survivors in Europe found twelve usable studies from 979 published between 1989 and 2022, with limited-duration prevalence between 450 and 1,240 persons per million and complete prevalence between 730 and 1,110 per million, and concluded that \"Information on prevalence of CCS in Europe is fragmented and inconsistent.\" Nobody knows accurately how many European survivors there are to plan services for.","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Childhood_cancer","links":[{"label":"PanCare network","url":"https://www.pancare.eu/"},{"label":"PanCareSurFup consortium","url":"https://www.pancaresurfup.eu/"},{"label":"The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries (Eur J Epidemiol 2018)","url":"https://doi.org/10.1007/s10654-018-0370-3"},{"label":"Fertility preservation for female patients with childhood, adolescent and young adult cancer: PanCareLIFE and IGHG recommendations (Lancet Oncol 2021)","url":"https://doi.org/10.1016/S1470-2045(20)30594-5"},{"label":"A multi-country evaluation of healthcare professionals' experiences with the PanCareFollowUp training package (Support Care Cancer 2026)","url":"https://doi.org/10.1007/s00520-026-10930-5"},{"label":"Prevalence of childhood cancer survivors in Europe: a scoping review (EJC Paediatric Oncology 2024)","url":"https://doi.org/10.1016/j.ejcped.2024.100155"}],"tags":["rejuvenation","survivorship","paediatric","late-effects","cohort","europe"],"related":["ccss","sjlife","bccss","ighg","rejuv-paed-second-cancers","rejuv-paed-fertility-female","rejuv-paed-fertility-male","idea-acc-aya-survivorship-passport"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-survivorship","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The PanCareSurFup cohort counts people, not clinical examinations: it is built for incidence of mortality, second cancers and cardiac events, not for the prevalence of everyday chronic conditions."],"url":"https://www.pancare.eu/","holds":"Pooled European data on five-year survivors of childhood and adolescent cancer, assembled for the study of late mortality, second cancers and cardiac events, together with the PanCare network's guidelines, survivorship passport and follow-up care intervention.","license":"Access by application through the consortium","maintainer":"PanCare network, with the PanCareSurFup data centre in Mainz"},{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","aka":["PanCAN","src-pancan"],"tldr":"PanCAN is the leading pancreatic cancer patient organisation; it pioneered free tumour molecular profiling for patients (Know Your Tumor) and runs an adaptive platform trial for a disease with few options.","summary":"Founded 1999. Know Your Tumor showed that ~25% of pancreatic cancers have actionable alterations and that matched therapy improved survival (Pishvaian, Lancet Oncol 2020), influencing NCCN's recommendation for germline and somatic testing in all patients. Precision Promise is a Bayesian adaptive phase 2/3 platform (first readouts 2024). PanCAN's Patient Services provide free case management, clinical trial finder and dietitian access; its advocacy helped double federal pancreatic cancer research funding.","asOf":"2026-09-08","links":[{"label":"PanCAN","url":"https://pancan.org/"},{"label":"Know Your Tumor outcomes (Lancet Oncol 2020)","url":"https://doi.org/10.1016/S1470-2045(20)30074-7"},{"label":"PanCAN news","url":"https://pancan.org/news/"}],"tags":["gap-fill","patient-org","source","patient"],"related":["pancreatic","cgp","germline-testing","basket-umbrella-platform"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tumour-agnostic"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-pishvaian-lancet-oncol"],"journals":[],"dependsOn":[],"notes":[],"url":"https://pancan.org/","holds":"Pancreatic cancer news, Patient Services case management, Know Your Tumor molecular profiling programme, Precision Promise adaptive platform trial, research grants and the annual 'State of the Science' reports.","license":"Copyright PanCAN","maintainer":"PanCAN"},{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","aka":[],"tldr":"Pathology AI benchmarks are the open challenge datasets on which every pathology model is scored: CAMELYON16 and 17 for lymph node metastasis detection, PANDA for prostate grading with 11,000 biopsies, and TCGA slide-level tasks used to compare foundation models. Licences are mostly CC BY-NC-SA or set per challenge.","summary":"Pathology AI benchmarks are the exam papers on which every pathology model is graded. The open challenge datasets include CAMELYON16 and CAMELYON17 for lymph node metastasis detection, PANDA for prostate grading, and TCGA-derived slide-level tasks used to compare foundation models. PANDA, with 11,000 biopsies, remains the largest public prostate grading set, and leaderboards such as eva and HEST aggregate results across models. The datasets are maintained by Grand Challenge, Radboud UMC and partners, under CC BY-NC-SA or per-challenge terms. The collection is referenced by the AI in oncology roadmap, which traces the field from pattern readers through foundation models to agents in the workflow.","asOf":"2026-09-08","links":[{"label":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","url":"https://panda.grand-challenge.org"}],"tags":["data","benchmark"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://panda.grand-challenge.org","holds":"Open challenge datasets for lymph node metastasis (CAMELYON16/17), prostate grading (PANDA), and TCGA-derived slide-level tasks used to compare foundation models.","license":"CC BY-NC-SA and per challenge","maintainer":"Grand Challenge / Radboud UMC and partners"},{"id":"penny-brohn-uk","kind":"collection","name":"Penny Brohn UK","aka":[],"tldr":"Penny Brohn UK runs free courses and sessions on living well with cancer, in person in Bristol and online across the UK.","summary":"Penny Brohn UK is a charity that offers a whole-person approach alongside medical treatment. Its Living Well course covers eating, moving, resting and coping, and it provides free individual sessions with nutritional therapists, counsellors and other practitioners. Services are free to people with cancer and their supporters, funded by donations. It does not offer alternative treatment and works alongside the NHS.","asOf":"2026-09-17","links":[{"label":"Penny Brohn UK","url":"https://www.pennybrohn.org.uk/"}],"tags":["free","patient-org"],"related":["maggies-centres","livestrong-at-the-ymca","look-good-feel-better","imerman-angels","first-descents","kesem"],"cancers":[],"sections":[],"technologies":["exercise-oncology","psycho-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.pennybrohn.org.uk/","holds":"Free Living Well courses and one-to-one services for people with cancer and their supporters, in Bristol and online, covering nutrition, physical activity, sleep, stress and emotional wellbeing.","maintainer":"Penny Brohn UK"},{"id":"prostate-cancer-promise","kind":"collection","name":"PROMISE registry: free germline testing in prostate cancer","aka":[],"tldr":"Men with prostate cancer in the US can get a free inherited-risk gene test by joining the PROMISE registry, which also offers counselling about the result.","summary":"PROMISE (Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness) is a research registry led by academic prostate cancer groups. Any man with a prostate cancer diagnosis in the United States can enrol online; the study sends a saliva kit, runs a multi-gene germline panel at no charge, and returns the result with access to genetic counselling. Men found to carry a pathogenic variant are followed for outcomes and told about trials that fit. The point of the registry is that guideline-recommended germline testing in prostate cancer is often skipped, and a free direct route removes one reason.","asOf":"2026-09-17","links":[{"label":"PROMISE registry: free germline testing in prostate cancer","url":"https://www.prostatecancerpromise.org/"}],"tags":["free","patient-programme"],"related":["prostate-cancer-foundation","pancan-know-your-tumor","nhs-genomic-medicine-service","nhs-jewish-brca-testing"],"cancers":["prostate"],"sections":[],"technologies":["germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.prostatecancerpromise.org/","holds":"A research registry that offers men with prostate cancer in the United States a free at-home germline test for inherited cancer genes, with genetic counselling for those found to carry a change and follow-up over time.","maintainer":"PROMISE study team (University of Washington and Fred Hutchinson Cancer Center)"},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","aka":[],"tldr":"Michael Milken's prostate cancer foundation, which funded the science behind abiraterone, enzalutamide and PSMA therapy and runs a precision-oncology network in US veterans' hospitals.","summary":"Founded 1993 (as CaP CURE). PCF-funded research contributed to abiraterone, enzalutamide, radium-223, PSMA imaging and radioligands, and germline testing guidance; the PCF-VA network provides genomic testing and trials to veterans; the Young Investigator awards have trained a generation of researchers. Patient resources include the Prostate Cancer Patient Guide and a Black-community outreach programme; ZERO Prostate Cancer and Movember are major partner organisations for support and awareness.","asOf":"2026-09-08","links":[{"label":"PCF","url":"https://www.pcf.org/"},{"label":"ZERO Prostate Cancer","url":"https://zerocancer.org/"},{"label":"Movember","url":"https://us.movember.com/"}],"tags":["gap-fill","patient-org"],"related":["prostate","psma","androgen-receptor","psma-pet","pluvicto","abiraterone","enzalutamide"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["castration-resistance","psa"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.pcf.org/","holds":"The largest philanthropic funder of prostate cancer research (>$1 billion), Challenge Awards and Young Investigator programme, the PCF-VA Precision Oncology Program, patient guides, and the annual Scientific Retreat.","license":"Copyright PCF","maintainer":"PCF"},{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","aka":[],"tldr":"PubMed and Europe PMC together form the searchable index of the biomedical literature; every claim here should trace back to something in them.","summary":"PubMed and Europe PMC together index the biomedical literature, more than 37 million citations with full text for open-access articles, and every claim on OnCo should trace back to something in them. PubMed is run by the NLM and Europe PMC by EMBL-EBI; both are public. Europe PMC adds text-mined annotations and preprints on top of the shared record. On OnCo the pair is cited by the bottlenecks Failures are hidden, Preclinical results do not reproduce, Knowledge reaches practice too slowly, Secrecy and intellectual property block collaboration and Misinformation and unproven therapies, and by ideas such as A replication status badge on every cancer paper, visible in PubMed and Funded living systematic reviews for every major cancer indication.","asOf":"2026-09-04","links":[{"label":"PubMed & Europe PMC","url":"https://pubmed.ncbi.nlm.nih.gov"}],"tags":[],"related":["src-semantic-scholar","src-dimensions"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["advances-in-cancer-research","american-journal-of-clinical-oncology","bba-reviews-on-cancer","cancer-letters","cancer-reports","cancer-treatment-and-research","cancer-treatment-reviews","cellular-oncology","clinical-advances-in-hematology-and-oncology","critical-reviews-in-oncogenesis","current-oncology-mdpi","current-oncology-reports","current-problems-in-cancer","current-treatment-options-in-oncology","experimental-oncology","expert-review-of-anticancer-therapy","in-vivo","international-journal-of-oncology","japanese-journal-of-clinical-oncology","journal-of-cancer-research-and-therapeutics","klinicka-onkologie","magyar-onkologia","medical-oncology","molecular-carcinogenesis","neoplasia","neoplasma","oncology-karger","oncology-reports","oncology-research-and-treatment","recent-results-in-cancer-research","gulf-journal-of-oncology","trends-in-cancer","tumori","veterinary-and-comparative-oncology","chinese-journal-of-oncology","medrxiv","biorxiv","current-opinion-in-oncology","journal-of-cancer-education","journal-of-psychosocial-oncology","nar-cancer","recent-patents-on-anti-cancer-drug-discovery","seminars-in-oncology-nursing","surgical-oncology-clinics-of-north-america","the-cancer-journal"],"dependsOn":[],"notes":[],"url":"https://pubmed.ncbi.nlm.nih.gov","holds":"Biomedical literature (>37M citations) with full text for open-access articles.","license":"Public","maintainer":"NLM; EMBL-EBI"},{"id":"ronald-mcdonald-house-charities","kind":"collection","name":"Ronald McDonald House Charities","aka":[],"tldr":"Ronald McDonald Houses give families of seriously ill children, including children with cancer, a free or low-cost place to stay next to the hospital.","summary":"Ronald McDonald House Charities runs hundreds of Houses and hospital Family Rooms worldwide. Families of children in treatment can stay close to the hospital, often for the whole course of treatment, at no or nominal cost; referral comes from the hospital's social work team. For childhood cancer, where treatment runs for months at a specialist centre, it is one of the largest sources of free lodging.","asOf":"2026-09-17","links":[{"label":"Ronald McDonald House Charities","url":"https://rmhc.org/"}],"tags":["free","patient-programme"],"related":["acs-road-to-recovery","acs-hope-lodge","corporate-angel-network","nhs-healthcare-travel-costs-scheme","young-lives-vs-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://rmhc.org/","holds":"Free or low-cost accommodation and meals for families of children being treated in hospital, at Ronald McDonald Houses near children's hospitals in many countries, plus Family Rooms inside hospitals.","maintainer":"Ronald McDonald House Charities"},{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","aka":[],"tldr":"The San Antonio Breast Cancer Symposium, run by UT Health San Antonio, the AACR and Baylor, packs the year's breast cancer evidence into one week each December. Abstracts are free and appear in Cancer Research and Clinical Cancer Research supplements.","summary":"The San Antonio Breast Cancer Symposium (SABCS) packs the year's breast cancer evidence into one week each December. It is the breast cancer meeting, run by UT Health San Antonio, the AACR and Baylor, and its abstracts appear in Cancer Research and Clinical Cancer Research supplements. Abstracts are free. On OnCo it is tagged source and congress, and the institution record Mays Cancer Center at UT Health San Antonio links to it as the meeting it hosts.","asOf":"2026-09-08","links":[{"label":"San Antonio Breast Cancer Symposium","url":"https://www.sabcs.org/"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mays-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.sabcs.org/","holds":"The breast cancer meeting; abstracts in Cancer Research and Clinical Cancer Research supplements.","license":"Abstracts free","maintainer":"UT Health San Antonio, AACR, Baylor"},{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings: Oncology","aka":[],"tldr":"The SCImago Institutions Rankings score research institutions in the Oncology subject area on three measures: research output drawn from Scopus, innovation measured by patents, and societal impact measured by web visibility. On OnCo it is a cross-check against the Nature Index, since the two draw on different publication sets.","summary":"The SCImago Institutions Rankings publish a bibliometric ranking of institutions specifically in the Oncology subject area, scoring each on research, innovation and societal impact. The research component draws on Scopus output, innovation on patents and societal impact on web visibility. The ranking is produced by SCImago Lab and is public. On OnCo it serves as a cross-check against the Nature Index when weighing the research standing of the institutions in its tables, since the two rankings draw on different publication sets and metrics.","asOf":"2026-09-04","links":[{"label":"SCImago Institutions Rankings: Oncology","url":"https://www.scimagoir.com/rankings.php?area=2730"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.scimagoir.com/rankings.php?area=2730","holds":"Institution ranking in the Oncology subject area by research, innovation, and societal impact.","license":"Public","maintainer":"SCImago Lab"},{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","aka":[],"tldr":"SEER records how many people in the US get each cancer and how long they live, by stage, age, race, and year.","summary":"SEER, the Surveillance, Epidemiology, and End Results programme, holds US cancer incidence, survival and prevalence statistics collected since 1973, broken down by stage, age, race and year of diagnosis. It is run by the NCI and the statistics are public; SEER*Explorer provides interactive access, and the data underpin most published US survival figures. On OnCo it is cited by the bottlenecks The hardest cancers are found late, Survivorship and late effects are neglected, Data silos, Weak real-world evidence and registries and Funding follows fashion, not burden. It also supports ideas such as A live national dashboard of stage at diagnosis as the scorecard for early detection and Randomise inside the cancer registry: registry-based trials for everyday questions.","asOf":"2026-09-04","links":[{"label":"SEER (Surveillance, Epidemiology, and End Results)","url":"https://seer.cancer.gov"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-registry-management"],"dependsOn":[],"notes":[],"url":"https://seer.cancer.gov","holds":"US cancer incidence, survival, and prevalence statistics since 1973.","license":"Public","maintainer":"NCI"},{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","aka":[],"tldr":"Semantic Scholar offers free literature search with machine-generated summaries and citation context.","summary":"Semantic Scholar is an AI-powered literature search from the Allen Institute for AI, holding citation graphs, machine-generated TL;DR summaries and citation context, with a free and open API. It updates continuously and is free to use. The API is a practical way to enrich person and trial pages with publication lists, and the citation context shows how a paper has been used by later work. On OnCo it is listed as a source with the tags source and data, one of the literature tools behind its people and trial pages.","asOf":"2026-09-08","links":[{"label":"Semantic Scholar","url":"https://www.semanticscholar.org/"}],"tags":["source","data"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.semanticscholar.org/","holds":"AI-powered literature search with citation graphs, TL;DRs, and a free API.","license":"Free; open API","maintainer":"Allen Institute for AI"},{"id":"sharsheret","kind":"collection","name":"Sharsheret","aka":[],"tldr":"Sharsheret offers Jewish women free access to genetic counsellors, peer supporters and social workers for breast and ovarian cancer and inherited risk.","summary":"Sharsheret is a US national organisation serving Jewish women and families, a community with a high rate of BRCA founder variants. Its genetics programme lets anyone speak with a certified genetic counsellor about family history, testing and results at no cost; its peer support network pairs callers with a woman who has had a similar experience; and its social workers help with the practical and emotional load. Services are free and open to all, regardless of background.","asOf":"2026-09-17","links":[{"label":"Sharsheret","url":"https://sharsheret.org/"}],"tags":["free","patient-org"],"related":["nhs-jewish-brca-testing","force-facing-our-risk"],"cancers":["breast-cancer","ovarian"],"sections":[],"technologies":[],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["hereditary-cancer-syndromes"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://sharsheret.org/","holds":"Free support for Jewish women and families facing breast and ovarian cancer or elevated genetic risk, including a genetics programme with genetic counsellors on staff, peer support and clinical social workers.","maintainer":"Sharsheret"},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","aka":[],"tldr":"The SNMMI Annual Meeting, held each June by the Society of Nuclear Medicine and Molecular Imaging, is where new PET tracers, radioligand therapy results and dosimetry work are first presented. Abstracts are free as a Journal of Nuclear Medicine supplement, and that journal carries the field's papers through the rest of the year.","summary":"The SNMMI Annual Meeting is the theranostics meeting, held each June by the Society of Nuclear Medicine and Molecular Imaging. It holds nuclear medicine and theranostics content: new tracers, radioligand therapy data and dosimetry. Abstracts are free as a Journal of Nuclear Medicine supplement, and that journal carries the field's papers through the rest of the year. On OnCo it is tagged source and congress, and it is linked from the journal record Journal of Nuclear Medicine and the institution record Society of Nuclear Medicine and Molecular Imaging.","asOf":"2026-09-08","links":[{"label":"SNMMI Annual Meeting","url":"https://www.snmmi.org/"}],"tags":["source","congress"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["snmmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"url":"https://www.snmmi.org/","holds":"Nuclear medicine and theranostics: new tracers, radioligand therapy data, dosimetry.","license":"Abstracts free (Journal of Nuclear Medicine supplement)","maintainer":"Society of Nuclear Medicine and Molecular Imaging"},{"id":"sjlife","kind":"collection","name":"St Jude Lifetime Cohort Study (SJLIFE)","aka":["SJLIFE","St. Jude Lifetime Cohort"],"tldr":"The study that brought survivors back to a hospital and tested them, rather than asking them what was wrong. It found that most of what it found had not been diagnosed: by age 45, on clinical testing, 95.5 per cent of survivors had a chronic health condition and 80.5 per cent had a serious, disabling or life-threatening one.","summary":"SJLIFE is the cohort that changed what the field believed, because it measured instead of asking. Everyone treated for a childhood malignancy at St Jude Children's Research Hospital who had survived ten years or more and was eighteen or older is eligible; participants are brought to the St Jude campus for a comprehensive evaluation, with limited home evaluation or survey-only participation offered as alternatives. The design paper describes those three levels of participation and reports that of the first 971 confirmed-eligible survivors contacted, 825 (91.8 per cent) agreed to take part, 88.6 per cent of them to comprehensive medical evaluation.\n\nThe 2013 report assessed 1,713 adult survivors, median age 32 (range 18 to 60), median 25 years from diagnosis (range 10 to 47), using systematic exposure-based medical assessments. The crude prevalence of adverse outcomes was highest for abnormal pulmonary function (65.2 per cent, 95 per cent confidence interval 60.4 to 69.8), hearing loss (62.1, 55.8 to 68.2), any endocrine condition (62.0, 59.5 to 64.6), any cardiac condition (56.4, 53.5 to 59.2) and neurocognitive impairment (48.0, 44.9 to 51.0). Liver dysfunction (13.0), osteoporosis (9.6), kidney dysfunction (5.0) and abnormal blood counts (3.0 per cent) were less common. Among survivors at risk after a specific treatment, the estimated cumulative prevalence at age 50 was 21.6 per cent for cardiomyopathy, 83.5 per cent for heart valve disorder, 81.3 per cent for pulmonary dysfunction, 76.8 per cent for pituitary dysfunction, 86.5 per cent for hearing loss, 31.9 per cent for primary ovarian failure, 31.1 per cent for Leydig cell failure and 40.9 per cent for breast cancer. At age 45 the estimated cumulative prevalence of any chronic health condition was 95.5 per cent (94.8 to 98.6) and of a serious, disabling or life-threatening one 80.5 per cent (73.0 to 86.6). The authors' own conclusion names what the method added: a systematic risk-based medical assessment \"identified a substantial number of previously undiagnosed problems\".\n\nThe 2017 cumulative-burden analysis went further and counted conditions rather than people. Of 5,522 eligible patients, 3,010 (54.5 per cent) had enrolled and had prospective clinical assessment. The cumulative incidence of chronic health conditions at age 50 was 99.9 per cent for grade 1 to 5 conditions and 96.0 per cent (95.3 to 96.8) for grade 3 to 5. By age 50 a survivor had experienced, on average, 17.1 conditions of any grade (16.2 to 18.1), of which 4.7 (4.6 to 4.9) were grade 3 to 5; matched community controls carried 9.2 (7.9 to 10.6) and 2.3 (1.9 to 2.7). Burden varied by primary diagnosis, highest in survivors of central nervous system malignancies (24.2, 20.9 to 27.5) and lowest in survivors of germ cell tumours (14.0, 11.5 to 16.6). Second neoplasms, spinal disorders and pulmonary disease were the major contributors to the excess.\n\nWhat SJLIFE cannot do is speak for everyone: it is one hospital's patients, better followed than almost any other group of survivors in the world, and 45.5 per cent of eligible patients were not clinically evaluable in the 2017 analysis. Its figures are the right ones to quote for what clinical testing finds, and the Childhood Cancer Survivor Study's are the right ones for a large multi-institution population answering a questionnaire.","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Cancer_survivor","links":[{"label":"St Jude Lifetime Cohort Study","url":"https://sjlife.stjude.org/"},{"label":"Prospective medical assessment of adults surviving childhood cancer: study design and feasibility of the St. Jude Lifetime Cohort (Pediatr Blood Cancer 2011)","url":"https://doi.org/10.1002/pbc.22875"},{"label":"Clinical ascertainment of health outcomes among adults treated for childhood cancer (SJLIFE) (JAMA 2013)","url":"https://doi.org/10.1001/jama.2013.6296"},{"label":"The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (Lancet 2017)","url":"https://doi.org/10.1016/S0140-6736(17)31610-0"}],"tags":["rejuvenation","survivorship","paediatric","late-effects","cohort"],"related":["ccss","bccss","pancaresurfup","rejuv-paed-chronic-disease-burden","rejuv-age-frailty-and-late-effects","idea-acc-national-late-effects-registry"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-survivorship"],"keyPapers":[],"journals":["journal-of-cancer-survivorship","pediatric-blood-and-cancer"],"dependsOn":[],"notes":["The two figures most often confused: 95.5 per cent is SJLIFE, by clinical testing, cumulative to age 45. 62.3 per cent is the Childhood Cancer Survivor Study, self-reported, at a mean age of 26.","Grades are a modified Common Terminology Criteria for Adverse Events scale applied to 168 chronic health conditions."],"url":"https://sjlife.stjude.org/","holds":"Clinically assessed health outcomes in adults treated for childhood cancer at St Jude, with systematic exposure-based medical testing rather than self-report, plus genomic and biospecimen data.","license":"Controlled access by application","maintainer":"St. Jude Children's Research Hospital"},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","aka":[],"tldr":"A head-shaving fundraiser that became the largest charitable funder of children's cancer research in the US, underwriting much of the cooperative-group trial infrastructure that treats most American children with cancer.","summary":"Started 2000 as a St Patrick's Day challenge; foundation formed 2004. Has granted >$350 million, including core support to the Children's Oncology Group (whose NCI funding covers only part of trial costs), the Pediatric Cancer Dream Team that developed immunotherapy approaches (CAR-T, GD2), the St. Baldrick's-Stand Up To Cancer collaborations, and Supportive Care Research grants. Also funds international scholars to build paediatric oncology capacity in LMICs.","asOf":"2026-09-08","links":[{"label":"St. Baldrick's","url":"https://www.stbaldricks.org/"}],"tags":["gap-fill","patient-org","paediatric"],"related":["all-leukemia","neuroblastoma","medulloblastoma","osteosarcoma","ewing-sarcoma","wilms-tumor","rhabdomyosarcoma","car-t","st-baldricks-foundation","paediatric-oncology-roadmap"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.stbaldricks.org/","holds":"The largest private funder of childhood cancer research grants in the US, including support for the Children's Oncology Group infrastructure, the Pediatric Cancer Dream Team (with Stand Up To Cancer) and international fellowships.","license":"Copyright St. Baldrick's","maintainer":"St. Baldrick's Foundation"},{"id":"src-stat-news","kind":"collection","name":"STAT News","aka":[],"tldr":"STAT News has the best-written reporting on the science and business of cancer, with real scepticism.","summary":"STAT News publishes health and biotech journalism across cancer science, drug pricing, policy and industry, with some of the best-written and most sceptical reporting on the science and business of cancer. It publishes daily from Boston Globe Media and is strong on radiopharmaceuticals, mRNA vaccines, access after approval and FDA politics. Access is freemium with a STAT+ subscription. On OnCo it is listed as a source with the tags source and news.","asOf":"2026-09-08","links":[{"label":"STAT News","url":"https://www.statnews.com/topic/cancer/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.statnews.com/topic/cancer/","holds":"Health and biotech journalism: cancer science, drug pricing, policy, and industry.","license":"Freemium; STAT+ subscription","maintainer":"Boston Globe Media"},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","aka":[],"tldr":"Susan G. Komen is the best-known breast cancer charity, founded in 1982. It has granted more than $1 billion for research, including early support for HER2-directed therapy, runs a helpline and treatment assistance programme, and holds ShareForCures, a patient-consented registry that shares data for metastatic breast cancer research.","summary":"Founded 1982. Beyond awareness (the pink ribbon), Komen funds research including early support for HER2-directed therapy and metastatic breast cancer studies, runs the Breast Care Helpline and Treatment Assistance Program, the Komen Tissue Bank at IU Simon (normal breast tissue), ShareForCures (patient-consented data and biospecimens), and advocates on stage IV disease, disparities (Stand for H.E.R. for Black women) and coverage of diagnostic imaging. Other key groups: Breast Cancer Research Foundation (research funding), Living Beyond Breast Cancer, METAvivor (metastatic research), Young Survival Coalition.","asOf":"2026-09-08","links":[{"label":"Susan G. Komen","url":"https://www.komen.org/"},{"label":"Breast Cancer Research Foundation","url":"https://www.bcrf.org/"},{"label":"METAvivor","url":"https://www.metavivor.org/"}],"tags":["gap-fill","patient-org"],"related":["breast-hr-positive","breast-her2-positive","tnbc","mammography","brca","src-lbbc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-health-disparities"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.komen.org/","holds":"Breast cancer patient helpline and financial assistance, ShareForCures patient-powered research registry, research grants (>$1 billion to date), the Komen Tissue Bank, and policy advocacy on screening and treatment access.","license":"Copyright Komen","maintainer":"Susan G. Komen"},{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","aka":[],"tldr":"Tahoe-100M is the biggest single-cell dataset ever released, built to teach AI how cancer cells respond to drugs.","summary":"Tahoe-100M is the largest single-cell dataset ever released, built to teach AI models how cancer cells respond to drugs. It comprises 100 million single-cell transcriptomes across 1,100 drugs and 50 cancer cell lines, making it the biggest perturbation atlas for training virtual cell models, and it was generated with the Mosaic platform to limit batch effects. It is used to train and benchmark State (Arc Institute perturbation model) and other perturbation models. The dataset was produced by Vevo Therapeutics with Parse Biosciences and the Arc Institute and is released openly under CC BY. It is referenced by the virtual cell roadmap, the AI in oncology roadmap and the drug discovery roadmap.","asOf":"2026-09-08","links":[{"label":"Tahoe-100M","url":"https://www.biorxiv.org/content/10.1101/2025.02.20.639398v1"}],"tags":["data","virtual-cell"],"related":[],"cancers":[],"sections":[],"technologies":["state-arc"],"targets":[],"drugs":[],"companies":["vevo-therapeutics"],"institutions":["arc-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.biorxiv.org/content/10.1101/2025.02.20.639398v1","holds":"100 million single-cell transcriptomes across 1,100 drugs and 50 cancer cell lines: the largest perturbation atlas for training virtual cell models.","license":"Open (CC BY)","maintainer":"Vevo Therapeutics with Parse Biosciences and Arc Institute"},{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","aka":[],"tldr":"Targeted Oncology is OncLive's sibling with a biomarker and targeted-therapy focus.","summary":"Targeted Oncology is OncLive's sibling title from MJH Life Sciences, with a biomarker and targeted-therapy focus. It publishes daily and holds precision oncology news, case-based discussions and approval coverage, and it is free to read. Its precision-oncology angle makes it a companion to OncLive for readers following biomarker-defined treatments and the approvals that go with them. On OnCo it is tagged source and news, and it is linked to the related OncLive record.","asOf":"2026-09-08","links":[{"label":"Targeted Oncology","url":"https://www.targetedonc.com/"}],"tags":["source","news"],"related":["src-onclive"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.targetedonc.com/","holds":"Precision oncology news, case-based discussions, and approval coverage.","license":"Free","maintainer":"MJH Life Sciences"},{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","aka":["TCGA","The Cancer Genome Atlas","GDC","Genomic Data Commons","GDC Data Portal","TCGA PanCanAtlas","Pan-Cancer Atlas"],"tldr":"The reference atlas of cancer genomes that most cancer biology since 2008 is built on.","summary":"The NCI Genomic Data Commons hosts The Cancer Genome Atlas, multi-omic data on more than 11,000 tumours across 33 cancer types, together with TARGET, CPTAC and other programmes. Mutations, copy number, RNA, methylation, protein and clinical data are harmonised into one portal, which is why it has become the training set for most cancer machine learning and the reference atlas that most cancer biology since 2008 is built on. The NCI maintains it; processed data are open and raw sequence is under controlled access. On OnCo it is tied to Whole-exome and whole-genome sequencing and DNA methylation profiling, and it is cited by the bottleneck Data silos, the paper TCGA Pan-Cancer Atlas, the Virtual cell roadmap and the Drug discovery roadmap.","asOf":"2026-09-04","links":[{"label":"TCGA / NCI Genomic Data Commons","url":"https://portal.gdc.cancer.gov"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["wes-wgs","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://portal.gdc.cancer.gov","holds":"Multi-omic data on >11,000 tumours across 33 cancer types (TCGA) plus TARGET, CPTAC, and others.","license":"Open (controlled access for raw sequence)","maintainer":"NCI"},{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","aka":[],"tldr":"The ASCO Post gives reliable, clinician-written summaries of the trials that matter, usually within days.","summary":"The ASCO Post carries news and expert commentary on trials, approvals, guidelines and oncology leadership, with clinician-written summaries of the trials that matter usually appearing within days. It is published by Harborside with ASCO, printing twice monthly and publishing daily online, and is free to read. It offers a good balance of data and expert perspective, and its congress coverage is thorough. On OnCo it is listed as a source with the tags source and news.","asOf":"2026-09-08","links":[{"label":"The ASCO Post","url":"https://ascopost.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://ascopost.com/","holds":"News and expert commentary on trials, approvals, guidelines, and oncology leadership.","license":"Free","maintainer":"Harborside / ASCO"},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","aka":[],"tldr":"The public archive of cancer scans that most radiology AI is trained and tested on.","summary":"The Cancer Imaging Archive (TCIA) holds de-identified cancer imaging, CT, MRI, PET and pathology, linked to TCGA and to clinical trials, and it is the main training and testing source for radiology AI models. It has over 200 collections, pairs with TCGA genomics for radiogenomics, and is accessed through the NBIA portal and the Imaging Data Commons. TCIA is run by the NCI with the University of Arkansas; most collections are CC BY, with terms set per collection. On OnCo it is tagged data, linked to the technology AI in radiology and the institution National Cancer Institute (NIH), and cited by the idea One certified open-source de-identification pipeline for scans and slides.","asOf":"2026-09-08","links":[{"label":"The Cancer Imaging Archive (TCIA)","url":"https://www.cancerimagingarchive.net"}],"tags":["data"],"related":[],"cancers":[],"sections":[],"technologies":["radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cancerimagingarchive.net","holds":"De-identified cancer imaging (CT, MRI, PET, pathology) linked to TCGA and clinical trials; the main training source for radiology models.","license":"Mostly CC BY; per-collection","maintainer":"NCI / University of Arkansas"},{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","aka":[],"tldr":"The Cancer Letter tells the inside story of cancer institutions and policy. Nobody else covers NCI and the centres this closely.","summary":"The Cancer Letter has published investigative reporting on cancer policy, the NCI, cancer centres, leadership and misconduct since 1973, and nobody else covers the NCI and the centres this closely. It appears weekly and is paywalled with some free content. It is essential for leadership changes, funding and governance stories, and light on trial data. On OnCo it is listed as a source with the tags source and news, read for the institutional story behind the science.","asOf":"2026-09-08","links":[{"label":"The Cancer Letter","url":"https://cancerletter.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://cancerletter.com/","holds":"Investigative reporting on cancer policy, NCI, cancer centres, leadership, and misconduct since 1973.","license":"Paywalled; some free","maintainer":"The Cancer Letter Inc."},{"id":"little-princess-trust","kind":"collection","name":"The Little Princess Trust","aka":[],"tldr":"The Little Princess Trust gives free real-hair wigs to children and young people up to 24 who lose their hair to cancer treatment.","summary":"The Little Princess Trust was founded by the parents of a girl who died of a Wilms tumour. It supplies free real-hair wigs, made from donated ponytails, to children and young people up to 24 across the UK and Ireland, fitted by approved salons, and has become one of the largest charity funders of childhood cancer research in the UK. Requests come through the charity's website or the hospital team.","asOf":"2026-09-17","links":[{"label":"The Little Princess Trust","url":"https://www.littleprincesses.org.uk/"}],"tags":["free","patient-org"],"related":["knitted-knockers","wigs-for-kids"],"cancers":[],"sections":["rejuvenation"],"technologies":["wigs-cranial-prosthesis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.littleprincesses.org.uk/","holds":"Free real-hair wigs for children and young people up to 24 who have lost their hair through cancer treatment or other conditions, made from donated hair, in the UK and Ireland; the charity also funds childhood cancer research.","maintainer":"The Little Princess Trust"},{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","aka":[],"tldr":"The Therapeutic Target Database lists every protein anyone has tried to drug, and what they tried.","summary":"The Therapeutic Target Database (TTD) lists therapeutic targets together with the approved and investigational drugs directed at each of them, which makes it a record of every protein anyone has tried to drug and what they tried. For each entry it records the target's validation status and the clinical stage reached by each drug, so a reader can see how far an attempt progressed. It is maintained by Zhejiang University and NUS and is free to use. OnCo lists it among its target and drug reference collections for tracing which targets have been pursued and with what.","asOf":"2026-09-04","links":[{"label":"Therapeutic Target Database (TTD)","url":"https://idrblab.org/ttd/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://idrblab.org/ttd/","holds":"Therapeutic targets and the approved and investigational drugs directed at them.","license":"Free","maintainer":"Zhejiang University / NUS"},{"id":"thesecondopinion","kind":"collection","name":"thesecondopinion","aka":[],"tldr":"In California, thesecondopinion gives adults with cancer a free review of their diagnosis and treatment plan by a panel of volunteer cancer specialists.","summary":"thesecondopinion has offered free second opinions in San Francisco since 1969. A patient sends their records; a panel of volunteer specialists from different disciplines reviews the pathology, imaging and plan, then meets the patient and family to explain their view, and sends a written report to the treating team. The service is limited to adults with a cancer diagnosis in California, and it is free because the clinicians volunteer their time.","asOf":"2026-09-17","links":[{"label":"thesecondopinion","url":"https://thesecondopinion.org/"}],"tags":["free","patient-programme"],"related":["cancer-commons"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://thesecondopinion.org/","holds":"Free multidisciplinary second opinions for adults with cancer in California: a panel of volunteer oncologists, surgeons, radiologists and pathologists reviews the case and meets the patient, with a written summary for the treating doctors.","maintainer":"thesecondopinion"},{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","aka":[],"tldr":"New Zealand's bowel, breast and cervical screening programmes are free for eligible people; Time to Screen is the one site that covers all three.","summary":"Time to Screen is the public face of New Zealand's National Screening Unit. It covers the National Bowel Screening Programme (a free home test for the eligible age range), BreastScreen Aotearoa (free mammograms) and the National Cervical Screening Programme (HPV testing, including self-testing, free for eligible groups). Each programme page states the current age range and who is eligible, which has changed in recent years as programmes have been extended.","asOf":"2026-09-17","links":[{"label":"Time to Screen (New Zealand national screening)","url":"https://www.timetoscreen.nz/"}],"tags":["free","public"],"related":["nhs-cancer-screening-programmes","australia-cancer-screening-programs","ireland-national-screening-service","cdc-nbccedp"],"cancers":["colorectal","breast-cancer","cervical"],"sections":[],"technologies":["colorectal-screening","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.timetoscreen.nz/","holds":"New Zealand's national bowel, breast and cervical screening programmes on one site: who is eligible, how to enrol and what happens next, in English and te reo Maori.","maintainer":"Health New Zealand, National Screening Unit"},{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","aka":[],"tldr":"The Triple Negative Breast Cancer Foundation runs a free site with information written for this subtype, a helpline staffed by oncology social workers, support groups, webinars and clinical trial listings. It is the dedicated patient resource for a subtype that general breast cancer sites cover only in passing.","summary":"The Triple Negative Breast Cancer Foundation offers support and information built specifically for triple-negative breast cancer: TNBC-specific information, a helpline, support groups, webinars and trial information. The helpline is staffed by oncology social workers. The TNBC Foundation maintains the site and it is free. It is the dedicated patient resource for a subtype that general breast cancer sites cover only in passing. On OnCo it is listed as a source with the tags source and patient.","asOf":"2026-09-08","links":[{"label":"Triple Negative Breast Cancer Foundation","url":"https://tnbcfoundation.org/"}],"tags":["source","patient"],"related":[],"cancers":["tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://tnbcfoundation.org/","holds":"TNBC-specific information, helpline, support groups, webinars, and trial information.","license":"Free","maintainer":"TNBC Foundation"},{"id":"uk-biobank","kind":"collection","name":"UK Biobank","aka":[],"tldr":"UK Biobank is the richest population cohort for linking genes, blood and imaging to who later develops cancer.","summary":"UK Biobank is the richest population cohort available for linking genes, blood and imaging to who later develops cancer. It holds half a million participants with genomes, imaging, proteomics and linked cancer registry and hospital records; whole-genome sequencing of all 500,000 participants was completed in 2023, Olink proteomics covers 3,000 proteins, and repeat imaging is under way. Researchers use it for polygenic risk, proteomic early detection and pretraining foundation models on healthy tissue. Access is for approved researchers, and the resource is maintained by UK Biobank Ltd, a charity. It is referenced by the technologies Biobanking and tissue procurement and Proteomics instruments and affinity platforms, and by the prevention roadmap.","asOf":"2026-09-08","links":[{"label":"UK Biobank","url":"https://www.ukbiobank.ac.uk"}],"tags":["data"],"related":["all-of-us"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.ukbiobank.ac.uk","holds":"Half a million participants with genomes, imaging, proteomics, and linked cancer registry and hospital records.","license":"Approved researchers","maintainer":"UK Biobank Ltd (charity)"},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","aka":["NHS hepato-pancreato-biliary cancer centres","HPB specialist centres (NPaCA Table 7)"],"tldr":"Where HPB cancer surgery happens in the UK: about two dozen specialist centres, each with a weekly specialist MDT that takes every treatment decision for gallbladder and bile duct cancer in its region.","summary":"NHS England commissions specialist HPB cancer surgery under service specification 2260 (September 2024), which requires a catchment of at least two million people, 150 liver operations a year for cancer and a weekly specialist MDT. The National Pancreatic Cancer Audit identifies the English centres by trust code (Table 7 of its 2025 methodology supplement, sourced from Pancreatic Cancer UK's centre list); Pancreatic Cancer UK also names the Scottish, Welsh and Northern Irish centres and AMMF keeps a parallel list of centres with cholangiocarcinoma expertise. This collection links the centres that have OnCo records; the UK and NHS page for gallbladder cancer lists the rest by name.","asOf":"2026-09-24","links":[{"label":"Pancreatic Cancer UK: your local specialist centre","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"},{"label":"NPaCA 2025 methodology supplement (Table 7)","url":"https://www.natcan.org.uk/wp-content/uploads/2025/11/NPaCA-SotN-2025-Methodology-Supplement.pdf"},{"label":"NHS England service specification 2260","url":"https://www.england.nhs.uk/wp-content/uploads/2024/09/2260-hpb-liver-service-specification.pdf"},{"label":"AMMF: centres with CCA expertise","url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/"}],"tags":["hpb","nhs","uk","centres"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-free-hospital","kings-college-hospital-london","imperial-cancer-centre","uclh","addenbrookes-cambridge","birmingham-cancer-centre","leeds-cancer-centre","newcastle-cancer-centre","manchester-royal-infirmary","liverpool-hpb-centre","southampton-cancer","oxford-cancer","nottingham-cancer-centre","leicester-cancer-research-centre","weston-park-sheffield","bristol-haematology-oncology-centre","derriford-plymouth","glasgow-royal-infirmary","royal-infirmary-edinburgh","morriston-swansea","university-hospital-wales-cardiff","belfast-trust-hpb","ammf","hull-castle-hill","royal-stoke-uhnm","uhcw-coventry","royal-surrey-guildford","royal-blackburn-elht","ninewells-dundee","aberdeen-royal-infirmary","raigmore-inverness","pancreatic-cancer-uk"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/","holds":"The NHS trusts and health boards that run specialist hepato-pancreato-biliary (HPB) cancer surgery and the specialist MDT for liver, bile duct, gallbladder and pancreatic cancers: 23 English trusts (the National Pancreatic Cancer Audit's Table 7, sourced from Pancreatic Cancer UK), the Scottish regional surgical centres, the South Wales centre and the Belfast Trust.","maintainer":"Pancreatic Cancer UK (list, updated November 2025); NHS England specification 2260 (model)"},{"id":"src-urotoday","kind":"collection","name":"UroToday","aka":[],"tldr":"UroToday is the prostate, bladder, and kidney cancer feed, including PSMA and radioligand news.","summary":"UroToday is the daily feed for prostate, bladder and kidney cancer, holding genitourinary oncology abstracts, conference coverage and expert video, including PSMA and radioligand news. It is published by Digital Science Press and is free with registration. Its conference coverage of ASCO GU, EAU, AUA and the PSMA conference is exhaustive, which makes it the quickest way to follow a genitourinary meeting without attending. On OnCo it is listed as a source with the tags source and news, read for the genitourinary cancers and for radioligand therapy news.","asOf":"2026-09-08","links":[{"label":"UroToday","url":"https://www.urotoday.com/"}],"tags":["source","news"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.urotoday.com/","holds":"Genitourinary oncology abstracts, conference coverage, and expert video.","license":"Free with registration","maintainer":"Digital Science Press"},{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","aka":[],"tldr":"In the US, the Vaccines for Children program gives the HPV vaccine free to children through 18 who are on Medicaid, uninsured or underinsured.","summary":"Vaccines for Children is the federal programme that buys vaccines for children who might otherwise go without. HPV vaccine is on the schedule, recommended at 11 to 12 and available through 18 under the programme. Eligibility is by insurance status; the vaccine itself is free, though a provider may charge an administration fee that cannot be a barrier to vaccination. For insured families, most plans must cover recommended vaccines without cost sharing.","asOf":"2026-09-17","links":[{"label":"Vaccines for Children program (US)","url":"https://www.cdc.gov/vaccines-for-children/"}],"tags":["free","public"],"related":["nhs-hpv-vaccination","gavi-hpv-programme"],"cancers":["cervical","head-and-neck"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":["gardasil-9"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.cdc.gov/vaccines-for-children/","holds":"Free vaccines, including HPV, for children and teenagers through 18 in the United States who are Medicaid-eligible, uninsured, underinsured or American Indian or Alaska Native, given through enrolled providers.","maintainer":"US Centers for Disease Control and Prevention"},{"id":"wigs-for-kids","kind":"collection","name":"Wigs for Kids","aka":[],"tldr":"Wigs for Kids gives children in the US who lose their hair to cancer treatment a free custom-made hairpiece.","summary":"Wigs for Kids has made hair replacements for children since 1981. Each is custom-fitted from donated hair so that a child can swim and play in it, and it is provided free to families of children under 18 with hair loss from any medical cause, including chemotherapy and radiotherapy. Applications are made through the website with a doctor's note.","asOf":"2026-09-17","links":[{"label":"Wigs for Kids","url":"https://www.wigsforkids.org/"}],"tags":["free","patient-org"],"related":["little-princess-trust","knitted-knockers"],"cancers":[],"sections":["rejuvenation"],"technologies":["wigs-cranial-prosthesis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.wigsforkids.org/","holds":"Free custom hair replacements for children under 18 in the United States who have lost their hair through chemotherapy, radiotherapy, alopecia, burns or other causes, made from donated hair.","maintainer":"Wigs for Kids"},{"id":"young-lives-vs-cancer","kind":"collection","name":"Young Lives vs Cancer","aka":[],"tldr":"Young Lives vs Cancer gives families of children and young people with cancer a free place to stay near the hospital and a social worker on the ward.","summary":"Young Lives vs Cancer, formerly CLIC Sargent, supports children and young people up to 25 with cancer in the UK. Its Homes from Home are free houses next to principal treatment centres where families stay for as long as treatment requires; its social workers, based in the hospitals, help with money, school, work and emotional support; and it gives registration grants and other financial help. All services are free.","asOf":"2026-09-17","links":[{"label":"Young Lives vs Cancer","url":"https://www.younglivesvscancer.org.uk/"}],"tags":["free","patient-programme","patient-org"],"related":["acs-road-to-recovery","acs-hope-lodge","corporate-angel-network","ronald-mcdonald-house-charities","nhs-healthcare-travel-costs-scheme"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.younglivesvscancer.org.uk/","holds":"Free Homes from Home accommodation near specialist children's and young people's cancer hospitals in the UK, social workers based in treatment centres, and grants for families of children and young people up to 25.","maintainer":"Young Lives vs Cancer (formerly CLIC Sargent)"}]